cells
Review
Oxidative Stress in Human Pathology and Aging: Molecular
Mechanisms and Perspectives
Younis Ahmad Hajam 1 , Raksha Rani 1 , Shahid Yousuf Ganie 2 , Tariq Ahmad Sheikh 2 , Darakhshan Javaid 2 ,
Syed Sanober Qadri 2 , Sreepoorna Pramodh 3 , Ahmad Alsulimani 4 , Mustfa F. Alkhanani 5 , Steve Harakeh 6 ,
Arif Hussain 7, * , Shafiul Haque 8,9, * and Mohd Salim Reshi 2, *
1
2
3
4
5
6
7
8
Citation: Hajam, Y.A.; Rani, R.;
Ganie, S.Y.; Sheikh, T.A.; Javaid, D.;
9
*
Department of Biosciences, Division Zoology, Career Point University, Hamirpur 176041, India;
younismajeed64@gmail.com (Y.A.H.); rakshasharma429@gmail.com (R.R.)
Toxicology and Pharmocology Laboratory, Department of Zoology, School of Biosciences and Biotechnology,
Baba Ghulam Shah Badshah University, Rajouri 185234, India; unikshahid@gmail.com (S.Y.G.);
sheikhtariq669@gmail.com (T.A.S.); djaved383@gmail.com (D.J.); sanoberqadrisyed@gmail.com (S.S.Q.)
Department of Life and Environmental Sciences, College Natural & Health Sciences, Zayed University,
Dubai P.O. Box 19282, United Arab Emirates; sreepoorna.unni@zu.ac.ae
Medical Laboratory Technology Department, College of Applied Medical Sciences,
Jazan University, Jazan 45142, Saudi Arabia; aalsulimani@jazanu.edu.sa
Emergency Service Department, College of Applied Sciences, AlMaarefa University,
Riyadh 11597, Saudi Arabia; mkhanani@mcst.edu.sa
King Fahd Medical Research Center; and Yousef Abdullatif Jameel Chair of Prophetic Medicine Application,
King Abdulaziz University, Jeddah 21589, Saudi Arabia; sharakeh@gmail.com
School of Life Sciences, Manipal Academy of Higher Education, Dubai P.O. Box 345050, United Arab Emirates
Research and Scientific Studies Unit, College of Nursing and Allied Health Sciences, Jazan University,
Jazan 45142, Saudi Arabia
Bursa Uludağ University Faculty of Medicine, Görükle Campus, Nilüfer 16059, Bursa, Turkey
Correspondence: dr.arifhussain@yahoo.co.in (A.H.); shafiul.haque@hotmail.com (S.H.);
reshisalim@gmail.com (M.S.R.)
Qadri, S.S.; Pramodh, S.; Alsulimani,
A.; Alkhanani, M.F.; Harakeh, S.; et al.
Oxidative Stress in Human Pathology
and Aging: Molecular Mechanisms
and Perspectives. Cells 2022, 11, 552.
https://doi.org/10.3390/
cells11030552
Academic Editors: Carsten Theiss
and Veronika Matschke
Received: 13 November 2021
Accepted: 24 January 2022
Published: 5 February 2022
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affiliations.
Abstract: Reactive oxygen and nitrogen species (RONS) are generated through various endogenous
and exogenous processes; however, they are neutralized by enzymatic and non-enzymatic antioxidants. An imbalance between the generation and neutralization of oxidants results in the progression
to oxidative stress (OS), which in turn gives rise to various diseases, disorders and aging. The characteristics of aging include the progressive loss of function in tissues and organs. The theory of aging
explains that age-related functional losses are due to accumulation of reactive oxygen species (ROS),
their subsequent damages and tissue deformities. Moreover, the diseases and disorders caused by
OS include cardiovascular diseases [CVDs], chronic obstructive pulmonary disease, chronic kidney
disease, neurodegenerative diseases and cancer. OS, induced by ROS, is neutralized by different
enzymatic and non-enzymatic antioxidants and prevents cells, tissues and organs from damage.
However, prolonged OS decreases the content of antioxidant status of cells by reducing the activities
of reductants and antioxidative enzymes and gives rise to different pathological conditions. Therefore,
the aim of the present review is to discuss the mechanism of ROS-induced OS signaling and their
age-associated complications mediated through their toxic manifestations in order to devise effective
preventive and curative natural therapeutic remedies.
Keywords: oxidative stress; reactive oxygen species; pathologies; mechanisms; aging
Copyright: © 2022 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
1. Introduction
distributed under the terms and
The foremost evolutionary outcome following various metabolic changes is the ability
to bind energy in the form of adenosine triphosphate (ATP). Enzymes involved in various
metabolic pathways produce energy through different biochemical reactions that prompt
the final reduction in molecular oxygen (O2 ). Different processes of amphibolic metabolic
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
Cells 2022, 11, 552. https://doi.org/10.3390/cells11030552
https://www.mdpi.com/journal/cells
Cells 2022, 11, 552
2 of 27
pathways such as the tricarboxylic acid (TCA) cycle and the respiratory chain are linked to
the inner mitochondrial membrane, which produces reactive oxygen species (ROS) and
generates free radicals. The generation of free radicals is a basic and useful incident for
the proper functioning, protection and survival of cells within physiological limits [1–3].
However, an imbalance in the generation and neutralization of ROS may lead to the accumulation of ROS intermediate products which are thought to be detrimental and may
induce oxidative stress (OS) [1,4,5]. ROS are essential for maintenance of homeostatic
environment for the cell survival, because they play a significant physiological role in
defense mechanisms [6]. Therefore, ROS are important for the survival as well as adaptation, for instance, hydrogen peroxide and superoxide anion are substantial factors which
are involved in the developmental signaling transduction in the pancreatic β-cells having
ability to control insulin secretion [7–9]. However, the concentration of ROS may increase
rapidly and reach toxic levels after calcium ion stimulation of the TCA cycle, an increase in
the activity of respiratory chains, the transport of electrons and the activity of NADPH [10].
Furthermore, oxidative stress may be increased in the cell or tissue if there will be elevation
in the rate of production and alleviation in the rate of neutralization of ROS [11]. Prolonged
higher OS leads to various life-threatening pathological conditions such as aging, heart diseases, diabetes, autoimmune diseases, cancer, neurological disorders, etc. [12]. Elucidating
the underlying mechanisms of OS-induced pathogenesis of numerous clinical conditions
and aging will help in the development of therapeutic agents against such diseases and
disorders for the overall well-being of humans.
1.1. Mechanism of ROS
Mitochondria are the primary endogenous source for ROS production due to their
role in the ATP production via oxidative phosphorylation, during which the molecular O2
becomes reduced into H2 O in electron transport chain (ETC). Mitochondrial superoxide
production is an important source of ROS in cells. Seven major sites of superoxide production are recognized in mammalian mitochondria. In a descending order of maximum
capacity, they are the ubiquinone binding sites in complex I (site IQ) and complex III (site
IIIQo), glycerol 3-phosphate dehydrogenase (GPDH.), the flavin in complex I (site IF), the
electron transferring flavor protein: Q oxidoreductase (ETFQOR) of fatty acid beta oxidation, and pyruvate and 2-oxoglutarate dehydrogenases. [13]. All these complexes release
O− 2 in the mitochondrial matrix except complex III site and GPDH. In the mitochondrial
membrane, superoxide dismutase is present in three forms viz. manganese superoxide
dismutase (Mn-SOD), copper superoxide dismutase and zinc superoxide dismutase. Manganese superoxide dismutase (Mn-SOD) converts O− 2 into hydrogen peroxide (H2 O2 ) and
then aconitase enzyme converts H2 O2 to a hydroxyl radical via Fenton reaction [14], while
copper superoxide dismutase and zinc superoxide dismutase change O− 2 into the inter
membrane space [15].
Another route of ROS generation is mitochondrial cytochrome catalytic cycle, it comprises Cytochrome P450 enzyme consisting of wide spectrum of organic compounds, such
as lipids, steroids, and xenobiotics. It produces various reactive byproducts such as superoxide radical and H2 O2 [16,17]. Moreover, in mammals, a range of protein complexes
also produce ROS, such as Nicotinamide adenine dinucleotide (NADH)-cytochrome b5 reductase (b5R) [18], dihydroorotate dehydrogenase (DHODH) [19,20], complex II: succinate
dehydrogenase (SDH) [21,22], and monoamine oxidases (MAO) [23]. Several defense
systems, in the form of antioxidants like GPXs, TRXPs, SODs, PRDXs, GSH, TRX2, GRX2,
cyt c oxidase (complex IV), coenzyme Q, ascorbic acid, vitamin E and carotenes, protect the
mitochondria from detrimental effects of ROS [23–26]. However, overproduction of ROS is
associated with different pathologies in human beings such as mitochondrial dysfunction,
cancer, inflammation, neurological and neurodegenerative diseases, diabetes, chronic renal
diseases, aging and DNA damage [27–30]. Genomic DNA and/or mitochondrial DNA
damage, mutations in somatic cells, instability in genome, oncogene activation, inhibition
of tumor suppressor genes, changes in various pathways of metabolism and signaling
–
–
Cells 2022, 11, 552
3 of 27
with the immediate activation of compensatory mechanisms, all contribute to cellular
damage [31,32] (Figure 1).
Figure 1. The mechanism for the production of ROS: Autoxidation with excess glucose alters the
overall metabolic process and produces free radicals, inhibiting the antioxidant enzymes (GPX,
CAT). ROS cause DNA damage. GPx: Glutathione peroxidase, CAT: Catalase, Trx: Thioredoxin,
GSIS: glucose-stimulated insulin secretion.
1.2. Mechanism of ROS-Mediated Toxicity
Cells always strive to maintain the level of ROS required for its normal functioning.
However, excess production of ROS reduces the activity of antioxidant enzymatic defense
system and also decreases the content of non-enzymatic proteins (GSH), hence affecting
the overall antioxidative defense system and making it unable to eliminate the surplus free
radicals. These excessive ROS are produced under hyperoxia and inflammatory conditions,
and a low or impaired antioxidant defense system, and finally alter the homeostasis of
the whole biological system. For instance, the oxidation of proteins and production of
carbonyl and nitrotyrosine, i.e., nitrosylation might decrease the activity of enzymes and
also reduces the production of growth factors that might result in cellular dysfunction [33].
One of the biomarkers for the assessment of ROS-mediated damage is lipid peroxidation
(LPO), which indicates the extent of peroxidative damage on membranous phospholipids
through the activation of sphingomyelinase activation and ceramide release and finally
causes cell death [34]. The excessive generation of ROS causes oxidative deoxyribonucleic
acid (DNA) damage. ROS can react with the nucleic acids by attacking the nitrogenous
bases and the sugar phosphate backbone, thus inducing single- and double-stranded DNA
breaks, which are also associated with premature aging [35].
1.3. ROS as Second Messengers
ROS can act as second messengers in some situations, and their optimum concentrations activate a variety of signal transduction pathways in the cell and facilitate the actions
of growth factors like cytokines, and Ca2+ signaling. Furthermore, the role of ROS can be
explained through the c-Jun N-terminal kinases (JNKs), a member of protein kinase family
Cells 2022, 11, 552
4 of 27
which is activated by ROS through the production of lipid peroxide intermediates and then
phosphorylated. Following its phosphorylation, it releases two B-cell lymphoma 2-related
proteins (BCL2) and sequestered in the cell [36,37]. After the release of these proteins, they
directly activate theBCL2-associated X (Bax) proteins through cytoplasmic anchor.
Hydrogen peroxide (H2 O2 ) is an essential metabolite involved in various redox
metabolic reactions and cellular processes. It has been identified that H2 O2 acts as a
sensor, modulator and signaling molecule during redox metabolism, and also works as
a second messenger along with hydrogen sulfide (H2 S) and nitric oxide (NO) [38–40].
Following the activation of these second messengers, they activate a downstream protein
cascade through specific oxidations, thus leading to the cellular metabolic response [41–43].
This metabolic response can influence proliferation, survival or death of the cell depending
on which downstream pathways (homeostatic, pathological or protective) have been activated [44]. In cells, H2 O2 is produced from various sources such as either a spontaneous or
catalytic breakdown of superoxide anion, produced through the partial reduction of oxygen
during aerobic respiration or through various oxidases, and is quickly converted into H2 O2
by superoxide dismutase present in the mitochondria or cytosol or in the extracellular
space [45–47] and regulatory machinery of the cell maintains the concentration in different
sub-cellular compartments.
In biological systems and in medicine, H2 O2 is used as anti-infective agent, such as for
the cleaning of wounds, due to its strong oxidative potential to kill microorganisms and
cells [38,48]. Hydrogen peroxide contributes to the maintenance of homeostatic metabolism,
because it is a key molecule in the Third Principle of the Redox Code “Redox sensing
by activating/deactivating cyclic production associated with NAD and NADP system
to support spatiotemporal organization of key processes” [49–51] of living organisms
and contributes to the regulation of cellular metabolism. H2 O2 diffuses through the cell
membrane through aquaporin water channels (AQP) transducing the redox signal from the
place where it is produced to a target site [52]. H2 O2 activates various transcription factors
in bacteria, lower eukaryotes and mammalian cells [53] and this stimulation finally leads to
a metabolic response of the cell to the original stimuli [54].
1.4. ROS Induces Multifaceted Alterations
An imbalance between free radicals and oxidants gives rise a tense-full situation in
the living system known as oxidative stress. Oxidative stress is a harmful process because
it adversely affects the structure of cell membranes, lipids, proteins, lipoproteins and
deoxyribonucleic acid (DNA) [55–61]. Likewise, the excessive production of hydroxyl
radicals and peroxynitrile leads to peroxidation of lipids; hence, this damages the cellular
membrane and lipoproteins. This in turn results in the formation of malondialdehyde
(MDA) and conjugated diene compounds; both of these are known as cytotoxic and
mutagenic compound. The rate of lipid peroxidation increases very rapidly and affects
a huge quantity of lipidic molecules [62]. Due to peroxidative damage, proteins are also
affected by OS, undergoing structural modifications that may indicate loss or an impairment
of their respective enzymatic activity [59,63].
Prolonged OS causes lesions in DNA; the most common base affected is guanine bases
in DNA and form 8-hydroxydeoxyguanosine (8-OHdG), which can bind to thymidine
rather than cytosine. The level of 8-OHdG is generally considered to be a pernicious DNA
lesion and is responsible for the mutagenesis [64]. Oxidative DNA damage can lead to
the loss of epigenetic information, possibly due to the damage in CpG island methylation
asset in promotor regions of a gene [65]. Moreover, it has been studied that 8-OHdG acts a
tissue biomarker of oxidative stress. Therefore, considering all these consequences, it can
infer that OS may induce various diseases (acute and chronic) speedup ageing processes
of cells and also causes acute pathologies (trauma and stroke). Prolonged and higher OS
leads to various life-threatening pathological conditions such as cardiovascular disease [66],
respiratory diseases [67,68], rheumatoid arthritis [69], neurological disorders [70], liver
and kidney diseases, reproductive diseases and diabetes [71,72]. Oxidative stress initiates
Cells 2022, 11, 552
5 of 27
various apoptotic signaling pathways due to increased production of ROS or reduction
in the activities antioxidative enzymes, disruption of intracellular redox homeostasis and
peroxidative damage in lipids, proteins or fragmentation of DNA. ROS-mediated toxic
manifestations have been explained in Figure 2.
Figure 2. ROS-mediated toxic manifestations such as ROS-mediated DNA damage; peroxidative
damage of membrane lipids, degradation of proteins caused ROS, Base modifications of Bases, where
MDA: Malondialdehyde, TBARS: Thiobarbituric acid-reactive species, *, unpaired electron.
1.5. Physiological Impacts of ROS
Reactive oxygen species (ROS) protect the body from pathogens such as microbes
and foreign agents. At a physiological level, ROS destroy pathogens; hence, they act as an
immune system to provide defense against foreign bodies [73], and are also used for the
formation of cell structures such as protein complexes [74]. Cells may produce ROS exogenously and they are used for intracellular signaling and also for exciting redox-sensitive
signaling pathways because ROS increase the production of cytoprotective regulatory
proteins [1,75]. Therefore, ROS control pro-inflammatory signaling, pro-fibrotic signaling,
the proliferation of cells, cell death and a variety of other biological processes without
activating a necessity for macromolecular damage [76,77].
The redox state of sulfur switches comprises three central proteins complexes such as
Cys/CySS, GSH/GSSG and thioredoxins (Trx) that maintains the equilibrium values of
redox protein complexes in cellular organelles [78,79]. For the maintenance of the structure
of proteins, trafficking of protein, enzyme regulation, signaling of cells and receptors,
various transcription factors sulfur switches are used widely [80]. An imbalance in the ROS
system in favor of surplus production of oxidants like hydroxyl ions might cause damage
Cells 2022, 11, 552
6 of 27
to the macromolecules, because the primary target of ROS including hydrogen peroxide
(a mild oxidant) is the –SH group of the Cys residues of the protein [81,82]. However,
thioredoxin and peroxiredoxin are able to reduce disulfide bonds and protein sulfenic acids
and act as mediators in redox signaling [83].
An accumulation in the ROS levels inside the cells leads to Cys oxidation residues in
intermembrane proteins such as kinases and phophatases due their contact with various
stimuli, eventually affecting the signal transduction processes [84]. The oxidized species
affect the growth factors, cytokines and hormones, or can induce the downregulatory effect
to signaling pathways such as PKa, mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) cascades [75]. Oxidants also inhibit the activity of phosphatases
via the oxidation of the reactive cys residue and inhibit its catalytic activity [85].
2. Effect of ROS on Human Health
The imbalance between the production and the elimination of free radicals leads to
OS inside the human body, which indicates that the level of oxidants overpowers the
antioxidant system and then these oxidants negatively affect the various cellular structures,
including membranes, proteins, lipids and DNA [1,86–90]. A well-known biomarker for
the assessment of (OS) is lipid peroxidation (LPO). The rate of LPO increases rapidly during
OS due to the peroxidative damage caused by free radicals on the polyunsaturated lipid
membrane. Moreover, OS also cause conformational changes in proteins, thus decreasing
their functional efficiency and alter their enzyme activities [89].
DNA damage and mutations induced by OS are associated with different human
pathologies including cancer. OS induces lesions in DNA, which reveals that ROS-induced
OS could lead to gene and chromosome mutations through DNA double-strand breaks
(DSBs) [91,92]. It has been reported that OS-induced DNA damage leads to the increased
production of mutagenic base8-oxo-2′ -deoxyguanosine levels in a tissue which acts as a
biomarker for OS [93].
ROS-induced OS causes alterations in different organ systems, which are explained
as follows:
1.
2.
3.
ROS-induced neurotoxicity causes modulation in the neurons such as permeabilization of the cellular membrane, a decrease in the excitability property of neuronal
membrane and the activation of the KATP pump (Figure 3).
ROS-induced oxidative stress also leads to cardiac myopathy due to the mitochondrial
damage, perforations in the mitochondria, the release of Cytochrome C and the
initiation of apoptotic cascade (Figure 3).
Liver and kidneys are the primary targets for ROS attack due to their direct involvement in metabolic and filtration processes. In the liver, ROS induce damages to the
hepatocyte membranes and leads to deuteriation, which in turn leads to the deposition
of collagen in the hepatocyte and finally cause liver fibrosis and cirrhosis. In addition,
the incomplete oxidation of biomolecules causes lipoapoptosis in hepatic cells and induces immune reactions in the liver (Figure 3). In the kidneys, ROS-induced oxidative
stress mainly initiates the production of various pro-inflammatory cytokines, which
initiates nephrotic inflammation and finally affects the renal functions (Figure 3).
Cells 2022, 11, 552
7 of 27
Figure 3. Effect
Effect of
of reactive
reactive oxygen
oxygen species
species (ROS).
(ROS). ROS generation
generation induces
induces Alzheimer’s
Alzheimer’s disease
disease by
by
accumulation
accumulation of
of ββ-Amyloid proteins, activation of BK and Kv and finally decreases excitability
property of neurons and neuro-degeneration of the heart, liver and kidneys, where KATP; ATPsensitive potassium, NADPH oxidase: Nicotinamide dinucleotide Phosphate reduced, p38MAPK;
p38 mitogen-activated protein kinases, MMP; Matrix metalloproteinases/tissue inhibitor of metalloα; Hypoxia
proteinases, HIFA-α; Hypoxia-inducible factor 1-alpha, FOXO1; Forkhead box transcription factors,
mPTP: mitochondrial permeability transition pore, PDK: Protein 3-phosphoinositide-dependent
protein kinase, NLRP:α:
Nucleotide-binding
oligomerization
MCP: Monocyte ChemoattracTumor necrosis factor
alpha,IL 1β:domain,
Interleukin
tant Protein, TNF-α: Tumor necrosis factor alpha, IL-1β: Interleukin-1 beta. Note: Upward arrows
indicate increase and downward arrows indicate decrease.
2.1. Role of ROS in Mitochondrial Dysfunction and in Diabetes Mellitus
Diabetes is a multifaceted metabolic disorder characterized by an abnormal increase
in blood glucose levels, which may or may be not associated with the reduced secretion
of insulin. Usually, the pancreatic beta cells adjust their secretion of insulin according
to the fluctuations in the concentration of glucose in blood, sensed by glucokinase, a
glucose sensor. However, during diabetes mellitus, glucose levels increase above the
normal range for a prolonged period of time. This chronic hyperglycemia has several
deadly negative impacts upon the structure and functions of different organs, viz. inducing
neuropathy, retinopathy, nephropathy, hepatic diseases and cardiovascular impediments.
These conditions arise due to the generation of superoxide radicals (O2 *), hydroxyl peroxide
and hydroxyl
radicalsin(OH*)
through
Due to damage
pancreatic
β auto-oxidation during the hyperglycemic condition.
Due to damage in pancreatic β-cells insulin secretion and signaling becomes hampered by mitochondrial toxicity or decreased oxygen supply to the mitochondria which
–
hinders glucose-stimulated insulin secretion from beta cells [94–96]. The dysfunction of the
mitochondria in these cells results in least formation of mitochondrial adenosine triphosphate which leads to the loss of glucose-stimulated insulin secretion [97,98]. Moreover,
autoxidized glucose results in mitochondrial DNA damage [99] and the initiation of vari-
–
tion) in the mitochondria of pancreatic β
Cells 2022, 11, 552
8 of 27
ous ROS-and RNS-generating pathways, which finally leads to endothelial dysfunction
(Figure 4). All these processes result in mitochondrial apoptosis and hamper ATP production [100–104]. Some studies have reported that insulin secretion might be hampered due
to overexpression of uncoupling protein 2 (negative controller of insulin secretion) in the
mitochondria of pancreatic β-cells, which leads to a decline in the generation of ATP and
glucose-stimulated insulin secretion [105,106].
Figure 4. Hyperglycemic condition is one of the major sources of ROS and leads to modulation
of various metabolic downregulatory pathways. Increased glucose results in auto-oxidation and
production of H2 O2 , ·OH and activation of downregulatory pathways such as PDX-1 and insulinβ: Pr Protein kinase-beta,
(mRNA) and increases the secretion, where DAG: Diacyl glycerol, PKC-β:
κB:
Nuclear
factor
kappa
light
chain
enhancer
of
activated
B
cells,
AGEs:
NF-κB: Nuclear factor kappa light chain enhancer of activated B cells, AGEs:Advanced
Advancedglycated
glycated end
end
β;
products, UDP-Glac-NAc: Uridine diphosphate N-acetylglucosamine, TGF-β; Transforming growth
factor beta, PDX1; pancreatic and duodenal homeobox-1, PARP: Poly (ADP-ribose) polymerase.
Closure of K+ -ATP-dependent channels results in membrane depolarization and activation of voltagedependent calcium channels, leading to an increase in intracellular calcium concentration; this
triggers pulsatile insulin secretion. Note: Upward arrows indicate increase and downward arrows
indicate decrease.
Hyperglycemic conditions during diabetes cause various complications such as
hyperglycemia-induced autoxidation, resulting in the production of H2 O2 and ·OH which
affect the synthesis of insulin by damaging the insulin-mRNA, and finally decrease the
content of insulin and also reduce the functional efficacy of the insulin response (Figure 4).
Moreover, autoxidized glycolytic intermediates increase the production rate of glycation
end product, initiate various pathways, such as the protein kinase C pathway, hexosamine
pathway and the polyol pathway (Figure 4). The downregulatory end products of all
these pathways ultimately lead to microvascular complications due to the accumulation of
collagen fibronectin and protein glycation products (Figure 4).
Cells 2022, 11, 552
9 of 27
2.2. Role of ROS in Obesity and Associated Comorbidities
Obesity is a chronic and complex disease involving an excessive amount of body fat
and body mass index of 30 kg/m2 or higher, which increases the risk for other diseases and
health-related problems, such as heart diseases [107], diabetes, high blood pressure and certain cancers. Due to serious health consequences, obesity is a leading cause of unnecessary
deaths worldwide. Various factors generating OS during obesity include hyperglycemia,
elevated tissue lipid levels, vitamin and mineral deficiencies, chronic inflammation, hyperleptinemia, increased muscle activity to carry excessive weight, endothelial dysfunction,
impaired mitochondrial function and type of diet. All of these complications lead to excessive production of ROS due to the weakening of the antioxidant system. Excessive
production of ROS is intricately associated with obesity and associated complications,
especially insulin resistance and type 2 diabetes.
Obesity-associated complications alter the signaling cascade in the body. One of
the common pathways which is significantly affected during obesity is leptin signaling
pathway. Leptin, a hormone having the ability to reduce the intake of food and body
weight, was initially considered for use in the treatment of obesity. However, it has been
reported that during obesity, the levels of circulatory leptin increase. It crosses the– blood–
brain-barrier (BBB) through a specific and saturable transporter. Therefore, at the neuronal
level leptin indicates the degree of obesity of an organism. It has been reported that with
the increase in adiposity, the serum leptin level also increases, which in turn leads to the
development of resistance at the level of the BBB transporter [108,109]. This indicates that
a smaller amount of leptin reaches the brain, thus leading to the activation of the signaling
pathway for weight regulation. In the brain, leptin binds with leptin NPY-AgRP-neurons,
which activate the NPY-1R and inhibit MC4-R on secondary neurons, finally leading to
an energy imbalance and energy consumption and increasing the accumulation of fat cell
mass (Figure 5).
Figure 5. The diagram shows the role of feedback mechanism of leptin, POMC neurons, and
NPY-AgRP neurons in the regulation of satiety and starving, where POMC: proopiomelanocortin,
NPY/AgRP: neuropeptide Y/Agouti-related protein, Lep-R: Leptin receptor, α-MSH: Alpha melaninstimulating hormone, MC4-R: Melanocortin receptor-4. Note: Upward arrows indicate increase and
downward arrows indicate decrease.
Cells 2022, 11, 552
10 of 27
2.3. Role of ROS in Cardiac Hypertrophy
Cardiac hypertrophy (CH) is an adaptive response of the heart to pressure overload. It
is a general pathological characteristic in the natural course of some major cardiovascular
diseases, such as hypertension and myocardial infarction. Cardiac hypertrophy is strongly
associated with a higher risk for heart failure and sudden cardiac death. OS is considered
as one of the important contributing factors in the development of cardiac hypertrophy.
Different pathways are involved in the development of hypertrophy like Angiotensin-II
(Ang II)-induced cardiac hypertrophy which is induced by an extracellular signal. ROS
also activate a broad variety of hypertrophy signaling kinases and transcription factors,
such as MAP kinase, NF-κB, etc. In addition to the profound alteration of cellular function,
ROS modulate the extracellular matrix function, evidenced by increased interstitial and
perivascular fibrosis. AngII stimulates the expression of the hypertrophic factor, betamyosin heavy chain genes in myocytes, and is mediated via ROS-dependent activation
of the extracellular-signal-regulated kinase signaling cascades [110]. A study was conducted
on guinea pigs to evaluate progressive left ventricular hypertrophy, and it has been found
that the expression of p22phox , p67phox , p47phox , Nox2 and Nox activity was upregulated
during the progression of cardiac hypertrophy to failure [111]. Additionally, Nox can be
stimulated by angiotensin-II to generate ROS, causing the activation of p38MAP kinase
following AP-1 activation, while it has also been confirmed that the activation of Rac1 is a
critical step in hypertrophy progression [112]. Moreover, NADPH oxidase also increases
the production of ROS, which further accelerates these pathways. ET-1 causes hydrolysis
of phosphatidylinositol 4,5-bisphosphate (PIP2) into IP3 and DAG, both these secondary
messengers activate calcium channels in the ER and releases Ca from it. Both Ca and KMUP1 activate the calcineurin, and it in turn actives NFATc4; finally, it increases AP-1 DNA
binding activity and initiates cardiac hypertrophy. ROS activation also activates HIF1-α,
cMyc, FOXO1 and PDK, and finally causes the activation of hypertrophic remodeling [113].
ROS also causes damage to the mitochondria, and cytochrome C is released from the
mitochondria, which finally leads to apoptosis [114–116]. All of these processes collectively
result in cardiac hypertrophy (Figure 6)
Figure 6. The diagram shows ROS-induced cardiac hypertrophy through the up-regulation of various
pathways. ROS induces the activation of endotjelin-1 protein which in turn causes break down of PIP3
α and
Cells 2022, 11, 552
11 of 27
into IP3 and DAG, both of these activates the calcium channels and releases calcium from endoplasmic reticulum. Liberation of Ca from ER inhibits the activation of Calcineurin, also mediated by
KMUP-1, and finally causes cardiac hypertrophy through the activation of AP-1DNA binding activity
of NFATc4. Moreover, ROS activates HIFI-1, FOXO-α and Myc pathways and leads to the activation
of hypertrophic remodeling. ROS also induce cardiac hypertrophy through the opening of mPTP
channel, release of cytochrome C and induction of apoptosis of myocardial muscles. Additionally,
ROS induces inhibition of P13K, Akt and GSK-3β. All these pathways induce cardiac hypertrophy,
where ET-1: Endothelin-1, mPTP: Mitochondrial Permeability Transition Pore, ASK-1: Apoptosis
signal-regulating kinase-1, MMP. TIMP: Matrix metalloproteinase/Tissue inhibitors of metalloproteinases, AP-1: Activator protein 1, NF-κβ: Nuclear factor-κ Beta, KATP; ATP-sensitive potassium,
NADPH oxidase: Nicotinamide dinucleotide phosphate reduced, p38MAPK; p38 mitogen-activated
protein kinases, HIFA-α; Hypoxia-inducible factor 1-alpha, FOXO1; Fork-head box transcription
factors, PDK: Protein 3-phosphoinositide-dependent protein kinase, NLRP: Nucleotide-binding
oligomerization domain, MCP: Monocyte Chemo-attractant Protein, TNF-α:Tumor necrosis factor
alpha, IL-1β: Interleukin-1 beta.
3. Oxidative Stress and Neurodegenerative Diseases
3.1. Alzheimer’s Disease
Neurodegenerative diseases impact not only the life quality of aging populations,
but also their life spans. All forms of neurodegenerative diseases have a wide range of
impact on the elderly. The major threat of these brain diseases includes progressive loss of
memory, Alzheimer’s disease (AD), impairments in the movement, Parkinson’s disease
(PD) and Huntington’s disease (HD). Alzheimer’s disease (AD) is one of the utmost neurodegenerative disorders that affect the elderly. During AD accumulation of amyloid beta
protein, neuronal or synaptic loss and brain atrophy in particular areas of the brain occurs.
AD affects the neocortex as well as the hippocampus; brain plaques and tangles are the
key characteristics of AD. An imbalance between the oxidant-antioxidant systems could
determine the degree of cellular damage. Oxidative stress and mitochondrial dysfunction
are key hallmark features of neurodegeneration [117], and plays an important role in the
progression of neuronal damage during AD [118]. This ROS-mediated neuronal damage
occurs due to the disruption of redox reaction, i.e., decrease in the activities of antioxidant
enzymes such as superoxide dismutase and catalase activities, and a decrease in the level
of antioxidants (ascorbic acid and tocopherol) favors the surplus ROS production along
with increased accumulation of Aβ in AD patients [119]. Aβ plaques are deposited in the
extracellular region of the endoplasmic reticulum and Golgi apparatus. This increase in the
deposition of Aβ plaques during initial stages of AD also increases oxidative stress and
finally leads to mitochondrial dysfunction [120,121]. Increased expression of amyloid mutant amyloid precursor protein and presenilin-1 increases the levels of hydrogen peroxide
(H2 O2 ) and lipid peroxidation [119,122]. It also promotes the phosphorylation of tau protein
in AD patients [119]. It has been studied that removal of cytoplasmic/zinc superoxide dismutase (SOD) drives the β-Amyloid protein oligomerization and memory Loss in a mouse
model of Alzheimer’s disease [123,124]. Previous studies reported that overexpression of
tau protein increases susceptibility of oxidative stress and reduction of peroxisomes [125].
Besides this, overexpressed mutant tau proteins (P301S and P301L) decrease the activity
of nicotinamide adenine dinucleotide hydrogen-oxidoreductase, leading to mitochondrial
dysfunction. Both factors are responsible for the ROS production [126–128]. It has been
reported this mitochondrial dysfunction inhibits the efficient generation of adenosine
triphosphate (ATP) [119,129]. Moreover, mitochondrial dysfunction in neuronal cells also
downregulates the expression of electron transport chain (ETC) genes responsible for the
activation of pyruvate, cytochrome oxidase and α-ketoglutarate dehydrogenase [130,131].
ROS-induced inactivation of antioxidant enzyme activities such as superoxide dismutase (SOD), activation of p38 and phosphorylation of tau protein causes an accumulation
of neurofibrillary tangles, which are represented in Figure 7. Moreover, the role of ROS in
responsible for the activation of pyruvate, cytochrome oxidase and α
Cells 2022, 11, 552
12 of 27
activation of cdk5, the release of intracellular Ca2+ and the inhibition of the wnt pathway
wnt pathway, GSK3β
are also explained in Figure 7 Due to the inactivation of the wnt pathway, GSK3β becomes
activated and then favors the phosphorylation of tau proteins.
Figure 7. The diagram shows the involvement of reactive oxygen species and amyloid β in
Alzheimer’s disease, where Aβ; amyloid plaques, NFT: neurofibrillary tangles; AD: Alzheimer’s
disease, SOD: superoxide dismutase, CAT: Catalase, APP: Amyloid β (Aβ) precursor protein,
GSK3β: Glycogen synthase kinase-3, Wnt-1: Wingless and Int-1, Cdk5: Cyclin-dependent kinase-5,
PRx: peroxiredoxin, RCAN1: regulator of calcineurin 1.
3.2. Parkinson’s Disease
Parkinson’s disease is a progressive nervous system disorder that affects movement.
Common symptoms include tremors, slowness of movement, stiff muscles, unsteady walk
and balance and coordination problems. Symptoms start developing slowly, occasionally
starting with a barely noticeable tremor in just one hand. Tremors are common, but the
disorder also commonly causes stiffness or slowing of movement. Various sources and
mechanism are involved in the generation of ROS viz metabolism of dopamine itself,
mitochondrial dysfunction, iron, neuro-inflammatory cells, calcium and aging. The gene
product involved in the development of PD includes DJ-1, PINK1, parkin, alpha-synuclein
and LRRK2, and also impacts mitochondrial function in complex ways, leading to the
aggravation of ROS generation and vulnerability to OS. Moreover, OS influences the cellular
homeostatic processes including ubiquitin-proteasome system and mitophagy. Interaction
among all these mechanisms contribute to neurodegeneration in PD due to OS, which
damages important cellular pathogenetic proteins that causes surplus generation of ROS.
Parkinson’s disease (PD) is distinguished by discriminating neuronal loss of dopaminergic
neurons in the substantia nigra pars compacta (SNc) and reduced dopaminergic level
in the nigrostriatal dopaminergic pathway in the brain [132,133]. It is thought that OSinduced pathophysiological condition is the fundamental cause of Parkinson’s disease
(PD) [133,134]. Recent studies reported that decreased activity of respiratory complex I in
substatia nigra pars compacta of patients suffering from Parkinson’s disease may cause
excessive ROS generation and induce cellular loss of dopaminergic neurons [133–135].
Cells 2022, 11, 552
13 of 27
The inhibitors such as 1-methyl-4-phenyl 1,2,3,4-tetrahydrpyridine (MPTP) and its
metablites, 1-methyl4-phenylpyridinium (MPP+) of Complex I may lead to the cytotoxic
effects on the dopaminergic neurons, resulting in clinical parkinsonian phenotype, and induce nigral degeneration with cytoplasmic α-synuclein [136]. Genetic mutations in proteins
such as α-synuclein, parkin, and phosphatase and tensin homolog induce putative kinase
that were associated with the ancestral forms of Parkinson’s disease [133]. The functions of
mitochondria have been affected when these genes are mutated and increases ROS-induced
oxidative stress [133]. Some studies evidenced that point mutations and deletion in the
mitochondrial DNA might cause a defect(s) in complex I or mitochondrial dysfunction
in Parkinson’s disease [137] and encode Complex I subunits in patients suffering from
PD [137–139]
Moreover, ROS-induced destruction of dopaminergic neurons is shown in Figure 8.
ROS-induced oxidative stress decreases the level of reduced glutathione (GSH) in the
substantia nigra pars compacta of PD [140]. Increased oxidative stress accelerates the
rate of lipid peroxidation, due to the degradation of membranous polyunsaturated lipids
and degradation of protein, and ROS also induced the fragmentation of DNA. All these
processes ultimately lead to the damage of dopaminergic neurons and results in lack of
coordination among the body parts. Additionally, experimental studies conducted on
animal models have reported that the levels of Fe increase in the substantia nigra pars
compacta, which might arise due to dysfunctional transport of Fe to the mitochondria
during Parkinson’s disease [141,142].
ROS in
in Parkinson’s
Parkinson’s disease through the of dopaminergic
Figure 8. The diagram shows the role of ROS
neurons. ROS exerts oxidative stress on DNA leads to modification in base and causes fragmentation
in DNA. Peroxidative damage in lipids, loss of fatty acids, changes in plasma membrane and degradation of proteins. All these changes damage the dopaminergic neurons, where H2 O2 : Hydrogen
peroxide; ROS: Reactive oxygen species, GSH: Reduced glutathione, GSSG: Oxidized glutathione.
Cells 2022, 11, 552
14 of 27
4. Oxidative Stress and Chronic Kidney Diseases
Kidney diseases have become a serious health concern throughout the world. Late
diagnosis is one of the major concerns. The causes for increasing levels of kidney disease include various factors such as an increased rate of diabetes, high blood pressure, prescription
of allopathic medicines, xenobiotics, etc. These factors lead to the formation of ROS and
cause oxidative stress in the renal system. Oxidative stress is one of the major progressive
threatening factors which is responsible for the increasing prevalence of chronic kidney
diseases (CKD) or end-stage renal diseases (ESRD), and may even lead to death [143,144].
It has been reported that during initial stages of CKD, the intensity of oxidative stress
becomes accelerated [145], which autonomously results in the development of ESRD [146].
This progression from CKD to ESRD has been observed in patients undergoing Hemodialysis (HD) [146,147]. Patients with ESRD on peritoneal dialysis (PD) have amplified OS
in comparison to non-dialysis uremic patients; however, it is less when compared with
patients undergoing HD [148,149]. In the kidneys, OS is responsible for progressive kidney
damage, such as lesions to the glomeruli, renal ischemia, apoptosis and cell death, intensifying the unadorned ongoing inflammatory processes. ROS-induced OS modulates various
signaling pathways, enzymes and gene expressions in the renal system.
NADPH oxidase (Nox) leads to the production of reactive ROS and contributes significantly to the progression of renal diseases. Nox encompasses seven members (Nox
1–5, DUOX1, DUOX2), and all these isoforms differ from one another on the basis of their
respective functions: Nox1, Nox3 and Nox5 produce superoxide (O2 *− ), whereas DUOX1,
DUOX2 and Nox4 mainly produce hydrogen peroxide (H2 O2 ) [150]. For the activation
of Nox1, various membrane subunits, such as p22phox, cytosolic subunits p47phox and
p67phox, are required. Nox4 is the principal isoform of NADPH in the kidneys. Nox4 plays
a significant role in redox processes involved in diabetic nephropathy, acute kidney injury,
obstructive nephropathy, hypertensive nephropathy, renal cell carcinoma and other renal
diseases by activating many signaling pathways [151]. Even though Nox4 is found in different cells viz epithelial cells, podocytes, mesangial cells, endothelial cells and fibroblasts,
it can induce cell apoptosis, inflammation and fibrogenesis [152].
As mentioned in the previous section of this paper, amongst the DNA bases, guanine
is most susceptible to oxidative stress and 8-OH-dG (8-hydroxy-20–deoxy-guanosine) is
one of the abundant oxidative products of nucleic acids [153]. This results in oxidative
damage to nucleic acids and amplifies the signal for the commencement of consequent
tumors [154]. Other indicators of OS include oxidized low-density lipoprotein, advanced
glycation end products (AGEs), 8-hydroxyde-oxyguanosine and malondialdehyde (MDA),
which increase significantly in blood and other tissues in patients suffering from chronic
kidney disease [155]. AGEs interact with cells through a receptor system for advanced
glycation end products and the receptor for advanced glycation end-products (RAGE) [156],
which in turn stimulates the mitogen-activated protein kinase transduction pathway. Such
stimulation is responsible for the translocation of the p65 subunit of nuclear factor kappa B
from the nucleus into the cytoplasm of the cell; this further stimulates second messengers
and results in a subsequent increase in pro-inflammatory enzymes, cytokines and adhesion
molecules [157–159]
ROS-Mediated Cardio Vascular and Nephropathy
Cardiovascular disease is one of the major causes of death in the entire world, not only
in the common population but also in persons suffering from chronic kidney disease (CKD).
Therefore, it may be proposed that cardiovascular diseases and chronic kidney diseases
are interrelated with one another. Moreover, the number of patients with cardiovascular
diseases and chronic kidney disease cause increased morbidity and mortality among the
all-renal dysfunction spectrum. During cardiovascular diseases and nephropathy, the
overproduction of ROS induces stress and leads to the oxidation of LDL (oxLDL) and CM;
both of these causes affect Endothelin-1, which in turn activates NADPH oxidase (Nox)
and NO and finally leads to vasoconstriction. Moreover, ROS production can also directly
Cells 2022, 11, 552
15 of 27
cause nephropathy, including renal microcirculation dysfunction, renal medullary ischemia,
tubular necrosis and glomerular cell damage [160–162] (Figure 9). Additionally, Figure 9
demonstrates how elevated OS causes contrast-induced nephropathy characterized by
improper renal microcirculation, tubular necrosis and glomerular damage. Figure 9 also
shows how oxidative stress induces the oxidation of lipids, which causes arterial stiffness,
endothelial damage and atherosclerosis.
Figure 9. This diagram represents the role of ROS in the pathogenesis of cardiovascular cardiovascular diseases and contrast-induced nephropathy. Over produced reactive oxygen species such as
−
H2 O2 , ONOO− , *OH induces oxidative damage on lipids (OxLDL) and CM and leads in the production of Endothelin-1. Endothelin-1along with ROS-mediated inflammation causes arterial stiffness,
atherosclerosis, endothelial damage, tissue injury. Among the renal complications it causes renal
microcirculation dysfunction, renal medullary ischemia, tubular necrosis and damages glomerular
injury. Were, OxLDL: Oxidized low-density lipoproteins, CM: Cell membrane, NO: Nitric oxide,
NADPH ox: nicotinamide adenine dinucleotide phosphate oxidase. Note: Upward arrows indicate
increase and downward arrows indicate decrease.
5. ROS in Aging and Age-Related Diseases
Reactive oxygen and nitrogen species (RONS) are generated through various endogenous and exogenous processes, and their undesirable effects are neutralized by antioxidant
defenses. Due to the imbalance between RONS generation and antioxidant defenses results in the induction of OS. Aging is a process during which tissues and organs lose
their functions or do not function efficiently. The OS theory regarding aging states those
age-associated functional losses occur due to the deposition of RONS-induced damages.
Simultaneously, OS is associated with various age-related circumstances (i.e., cardiovascular diseases [CVDs], chronic obstructive pulmonary disease, chronic kidney
– disease,
neurodegenerative diseases and cancer), including sarcopenia and frailty [163–165]. OSinduced aging and associated disorders cause deterioration in soft tissues and disrupt the
homeostasis [166,167].
–
–
Cells 2022, 11, 552
16 of 27
Moreover, OS induces abnormal signaling in mitochondria [168] which leads to
changes in mitochondrial homeostasis such as modulation in the signaling of ROS and
causes age-dependent cellular damage [169–171]. Progressive generation of ROS decreases
the activity of scavenger enzymes and favors situation towards a pro-oxidant status which
causes aging of cells [172–174]. It has been reported that depletion of mitochondrial superoxide
– dismutase and catalase causes elevation in OS in mice, which lead to premature aging
and age-associated pathogenic conditions [175]. This increased oxidative-stress-induced
mitochondrial dysfunction leads to aging of cells by reducing the life span of cells due to
functional inefficiency of enzymes, proteins and other biomolecules [175–179] and accelerates –the peroxidative damage to membrane lipids, decreases fatty acids and degrades the
proteins (Figure 10).
Figure 10. This diagram represents the role of reactive oxygen species (ROS) in cellular ageing.
ROS-induced oxidative stress-induced damage in DNA (base alteration, fragmentation), peroxidative
damage in lipids, protein degradation and inhibition of repair. All these abnormal changes in the
cells decrease their working efficiency and causing their ageing. Were, GSH; Reduced glutathione,
GSSG: Oxidized glutathione. MDA, TBARS. Note: Dot (.) designates free radical.
ROS induce faults in replication and impair the mitochondrial DNA repair system, accumulation of aged protein and lipids and decrease the replicative capability of
DNA [180–185] (Figure 10).
–
Mitochondria-Associated Membranes Involvement with Aging
Sites of close
contactbody
between
and the the
endoplasmic
organism’s
with mitochondria
age. Aging influences
individual reticulum
function of(ER)
orare known as mitochondria-associated membranes (MAM) or mitochondria–ER contacts
(MERCs). They contribute significantly to both cell physiology and pathology. Aging is a
composite process associated with the steady weakening of cells, tissues and the entire function of an organism’s body with age. Aging influences the individual function of organelles,
including mitochondria and the endoplasmic reticulum (ER), and hence affects their contact
Cells 2022, 11, 552
17 of 27
sites. At the cellular level, aging was associated with oxidative stress, accumulation of
DNA modifications, impaired proteostasis and inefficient organelle turnover [186].
The endoplasmic reticulum (ER) and mitochondria are the chief intracellular organelles
that are dynamically connected through temporally form of contact, called as mitochondriaassociated membranes (MAMs). These contact sites are recognized due to their unique
molecular composition, which is specifically restricted to the surrounding of the interacting
membrane fragments. These molecular assemblies construct links in such a way that
they develop a unique local environment, which could increase the transfer of cargo or
signals among the different organelles. Previous studies have reported that MAMs form
a physical platform which enables communication between the ER and mitochondria,
which is associated with lipid biosynthesis. Moreover, the proteome of the MAMs fraction
remains on target during the various age-associated disorders including Alzheimer’s disease [187,188], amyotrophic lateral sclerosis [189,190] and type 2 diabetes mellitus [191,192],
as well as in obesity [193], GM1-gangliosidosis [194] and viral infections through human
cytomegalovirus or hepatitis C virus [195,196].
Aging is considered one of the most important factors responsible for causing elevated
ER stress and mitochondrial dysfunction, as well as the diminution of ER stress. Various
studies have also reported that ER–mitochondrial contact plays important role in the
biogenesis of mitochondrial-derived compartments [197–199], and these compartments
might play vital roles in cellular adaptation to environmental stress conditions [199]. Aging
is an important factor during which stress level increases in ER, which in turn leads to
the mitochondrial dysfunction [200]. Moreover, various studies have also suggested that
there is a correlation between spatial reorganization and elevated ATP levels, oxygen
consumption, reductive power and elevated mitochondria Ca2+ uptake [201,202]. However,
uncoupling of the organelles or blocking the Ca2+ transfer decreased the metabolic response,
interpreting cells and makes them more prone to ER stress [201,203]. Subsequently, ER
stress induces premature elevation in mitochondrial metabolism that relies mainly upon
organelle coupling and the transfer of Ca2+ [201–206].
6. The Role of ROS in the Induction of DNA Damage
6.1. Role of ROS in Mediating Genotoxin-Induced Damage
Cells are exposed to endogenous as well as exogenous sources of ROS. Surplus level of
ROS impairs physiological function through the cellular damage of DNA, proteins, lipids
and other macromolecules. ROS-mediated harmful effects contribute to the progression of
deteriorating conditions in human beings including neurodegenerative disorders, cardiac
dysfunction, cancer, aging, etc. ROS induce deleterious effect on cells, and also act as
stress-induced signaling molecules in cells. It has been reported that DNA damage is due to
the increased production of intracellular ROS, and there are various sources which damage
the DNA by ROS, such as ionizing radiations, synthetic chemicals, pesticides, etc.
Genotoxicity caused due to chemotherapeutics such as doxorubicin and cisplatin
elevates the level of ROS, inhibits the antioxidant system such as antioxidants (GSH, and
ascorbic acid), enzymes responsible for the regeneration of antioxidants, SOD, CAT and
peroxidases [207,208]. The ROS causes perforation in the mitochondrial membrane and
cytochrome C gets released and initiates the apoptosis. Moreover, cytochrome C, AfAP
and Caspase 9 activate Caspase 3, which leads to the activation of PARP and finally causes
DNA fragmentation (Figure 11).
Cells 2022, 11, 552
18 of 27
Figure 11. The diagram reflecting the role of cisplatin and Doxorubicin in the initiation of oxidative
stress and molecular changes. Cisplatin activates the CTR1 and OCT2, damage in mitochondria
(perforations), release of cytochrome, apoptosis and fragmentation in DNA. Doxorubicin induces the
production of superoxides and peroxide production; ROS inhibit the enzymatic activities. Doxorubicin directly binds to the aconitase enzymes, enters into the nucleus and leads the ROS-induced DNA
damage, where CRT1: The copper transporter CTR1 regulates1, OCT2; Organic cation transporter 2,
PARP: poly (ADP-ribose) polymerase, APf-1: Apoptotic protease factor 1, Cyt C: Cytochrome C,
Casp3, 9: Caspase3 and 9, and DSBs: Double-stranded breaks.NH3 , Cl, CSE. Note: Dot (.) designates
free radical.
The other forms of DNA are also damaged due to the direct induction of ROS, these
can oxidize nucleoside bases such as the formation of 8-oxo guanine, which can cause
transversion of G-T or G-A if unrepaired [209]. The base excision repair pathway is used
to recognize and repair oxidized bases, but when they are present simultaneously on
opposite strands, attempted base excision repair can cause the formation of double-strand
breaks [210]. The accumulation of ROS also induce lesion in the mitochondrial DNA, DNA
strand breaks and deprivation of mitochondrial DNA (Figure 11).
6.2. Role of ROS-NO in DNA Damage by Oncogenic Replication Stress
Cancer is caused due to alterations in critical regulatory genes that control cell proliferation, differentiation and survival. Studies have shown that specific genes called oncogenes
are able to induce cellular transformation, thereby providing the first insights into the
molecular basis of cancer.
DNA damage means physical or chemical changes to DNA in cells, which influence the
interpretation and transmission of genetic information. There are various cancer-causing
agents which are broadly divided into exogenous and endogenous; both of these include
chemicals, radiations, free radicals and topological changes, and each of these agents induce
distinct forms of damage [211]. Cells have evolved complex processes to deal with genomic
damage. Depending on the nature of cuts in DNA, particular pathways are activated
Cells 2022, 11, 552
19 of 27
to facilitate recognition of the impaired regions and their repair [212,213]. A specific
dangerous lesion is the DNA double-strand break (DSB), which may be mutagenic due
to chromosomal rearrangement. To reverse the DNA damage, cells produce a network of
events, known as the DNA damage response (DDR). This response includes recognition of
damaged DNA, activation of checkpoints, cell cycle arrest and, ultimately, the outcome for
repair, apoptosis and immune clearance [214,215]. The molecular components of the DSBinduced DDR have been studied broadly and broadly divided into three major groups viz.
sensors which helps in the identification of damage. The transducer helps in coordinating
the signaling and effectors, which ultimately facilitate the outcome [216–218].
ROS are well identified as mediators of DNA damage. Ionizing radiations (IR) induce
double-stranded breaks by high-energy damage to the sugar backbone of DNA, and also
through free radicals generated in cells—mostly •OH from water [22]. Chemotherapeutics
including doxorubicin and cisplatin enhances the level of ROS and play an important role
in their genotoxic effect [23,24]. It has been reported that ROS directly induce DNA damage
by oxidizing nucleoside bases (e.g., the formation of 8-oxo guanine) [25] and convert G-T
or G-A if unrepaired. The BER pathway identifies and repaired these oxidized bases [26].
Moreover, the accumulated ROS also induces lesions in mitochondrial DNA, breaks DNA
strands and also causes degeneration of mitochondrial DNA [27].
7. Conclusions
Reactive oxygen species (ROS) are generated through different endogenous and exogenous processes. Oxidative stress is due to an imbalance between the ROS production
and antioxidants defense and is progressive with ageing. Oxidative stress is also associated
with various chronic diseases and damages such as diabetes, neuro-degenerative diseases,
obesity, cardiac hypertrophy, hepatorenal damage, reproductive dysfunction, DNA damage, mitochondrial dysfunction and finally aging of cells. Biomarkers of OS might be useful
as diagnostic tool or therapeutic target. Further investigations are needed to evaluate the
efficacy of antioxidant supplements and natural polyphenolics from plant parts to combat
the pathologies caused by oxidative stress.
8. Future Perspective
Considering ROS-induced oxidative damages and diverse pathologies on different
organ systems, it can be seen that oxidative stress leads to the evolution of numerous and
diverse pathologies in the body. Further studies are required to elucidate the mechanisms
through which oxidative-stress-related signaling can contribute to the alteration of different
organs in order to devise effective preventive and curative therapeutic strategies. Various
reports have revealed that the use of antioxidants can treat many diseases; the development
of antioxidant therapies also represents a promising avenue for ROS pathology treatment.
Antioxidant therapy, such as the use of polyphenols, flavonoids, antioxidant supplements
and other nutritional compounds, together with moderate aerobic exercise, may reverse the
damage induced by oxidative stress. Therefore, the knowledge of a particular antioxidant’s
oxidative pathway associated with ROS could allow both the identification of disease
markers and the development of preventive and curative therapeutic strategies.
Author Contributions: Y.A.H.: conceptualization, methodology, investigation, formal analysis,
writing—original draft preparation; R.R.: conceptualization, methodology, investigation, formal
analysis, writing—original draft preparation; S.Y.G.: conceptualization, methodology, investigation, formal analysis, writing—original draft preparation; T.A.S.: conceptualization, methodology,
investigation, formal analysis, writing—original draft preparation; D.J.: conceptualization, methodology, investigation, formal analysis, writing—original draft preparation; S.S.Q.: conceptualization,
methodology, investigation, formal analysis, writing—original draft preparation; S.P.: conceptualization, methodology, investigation, formal analysis, validation, writing—original draft preparation; A.A.: conceptualization, supervision, project administration, writing—review and editing;
M.F.A.: conceptualization, supervision, project administration, writing—review and editing; S.H.
(Steve Harakeh): conceptualization, supervision, project administration, writing—review and edit-
Cells 2022, 11, 552
20 of 27
ing; A.H.: conceptualization, supervision, project administration, writing—review and editing; S.H.
(Shafiul Haque): conceptualization, supervision, project administration, resources, writing—review
and editing; M.S.R.: conceptualization, supervision, project administration, resources, funding acquisition, writing—review and editing. All authors have read and agreed to the published version of
the manuscript.
Funding: No financial support was available for this study.
Acknowledgments: The authors, S.Y.G., T.A.S., D.J., S.S.Q., M.S.R. are thankful to Central Library
and Departmental Library (Department of Zoology) of Baba Ghulam Shah Badshah University for
providing access to different Journals and books for writing this article. M.S.R. is also thankful to
University Grants Commission for providing Start-up Research Grant (No. F.30-441/2018 (BSR),
07-06-2018). The authors, Y.A.H. and R.R., are also grateful to the CM-Startup Scheme, Govt of
Himachal Pradesh for providing financial assistance under the project (HPSTARTUP/2020/12/03) to
Zoology Division, Career Point University, Hamipur, H.P. India. The authors, S.H. and A.A., sincerely
acknowledge Jazan University, Saudi Arabia, for providing the access of the Saudi Digital Library for
this research work.
Conflicts of Interest: The authors declare no conflict of interest.
References
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
Dröge, W. Free radicals in the physiological control of cell function. Physiol. Rev. 2002, 82, 47–95. [CrossRef]
Merry, T.L.; Ristow, M. Mitohormesis in exercise training. Free Radic. Biol. Med. 2016, 98, 123–130. [CrossRef] [PubMed]
Phaniendra, A.; Jestadi, D.B.; Periyasamy, L. Free radicals: Properties, sources, targets, and their implication in various diseases.
Indian J. Clin. Biochem. 2015, 30, 11–26. [CrossRef] [PubMed]
Keane, K.N.; Cruzat, V.F.; Carlessi, R.; de Bittencourt, P.I.H.; Newsholme, P. Molecular events linking oxidative stress and
inflammation to insulin resistance and β-cell dysfunction. Oxid. Med. Cell. Longev. 2015, 2015, 181643. [CrossRef]
Araki, E.; Nishikawa, T. Oxidative stress: A cause and therapeutic target of diabetic complications. J. Diabetes Investig. 2010, 1,
90–96. [CrossRef] [PubMed]
Finkel, T.; Holbrook, N.J. Oxidative stress and aging: Catalase is a longevity determinant enzyme. Nature 2000, 408, 239. [CrossRef]
Newsholme, P.; Cruzat, V.; Arfuso, F.; Keane, K. Nutrient regulation of insulin secretion and action. J. Endocrinol. 2014, 221,
105–120. [CrossRef]
Evans, J.L.; Goldfine, I.D.; Maddux, B.A.; Grodsky, G.M. Are oxidative stress-activated signaling pathways mediators of insulin
resistance and β-cell dysfunction? Diabetes 2003, 52, 1–8. [CrossRef]
Newsholme, P.; Haber, E.P.; Hirabara, S.M.; Rebelato, E.L.O.; Procópio, J.; Morgan, D.; Oliveira-Emilio, H.C.; Carpinelli, A.R.;
Curi, R. Diabetes associated cell stress and dysfunction: Role of mitochondrial and non-mitochondrial ROS production and
activity. J. Physiol. 2007, 583, 9–24. [CrossRef]
Newsholme, P.; Gaudel, C.; Krause, M. Mitochondria and diabetes. An intriguing pathogenetic role. Adv. Mitochon. Med. 2012,
235–247.
Sharifi-Rad, M.; Anil Kumar, N.V.; Zucca, P.; Varoni, E.M.; Dini, L.; Panzarini, E.; Rajkovic, J.; TsouhFokou, P.V.; Azzini, E.; Peluso,
I.; et al. Lifestyle, oxidative stress, and antioxidants: Back and forth in the pathophysiology of chronic diseases. Front. Physiol.
2020, 11, 694. [CrossRef]
Valko, M.; Leibfritz, D.; Moncol, J.; Cronin, M.T.; Mazur, M.; Telser, J. Free radicals and antioxidants in normal physiological
functions and human disease. Int. J. Biochem. Cell Biol. 2007, 39, 44–84. [CrossRef] [PubMed]
Brand, M.D. The sites and topology of mitochondrial superoxide production. Exp. Gerontol. 2010, 45, 466–472. [CrossRef]
[PubMed]
Vásquez-Vivar, J.; Kalyanaraman, B.; Kennedy, M.C. Mitochondrial aconitase is a source of hydroxyl radical: An electron spin
resonance investigation. J. Biol. Chem. 2000, 275, 14064–14069. [CrossRef] [PubMed]
Okado-Matsumoto, A.; Fridovich, I. Subcellular distribution of superoxide dismutases (SOD) in rat liver: Cu, Zn-SOD in
mitochondria. J. Biol. Chem. 2001, 276, 38388–38393. [CrossRef]
Yasui, H.; Hayashi, S.; Sakurai, H. Possible involvement of singlet oxygen species as multiple oxidants in p450 catalytic reactions.
Drug Metab. Pharmacokinet. 2005, 20, 1–13. [CrossRef] [PubMed]
Omura, T. Mitochondrial P450s. Chem. Biol. Interact. 2006, 163, 86–93. [CrossRef] [PubMed]
Zumárraga, M.; Andía, I.; Dávila, R.; Miller, J.C.; Friedhoff, A.J. Expression in normal and in subjects with schizophrenia of a
novel gene fragment originally isolated from monozygotic twins discordant for schizophrenia. Genet. Mol. Biol. 2004, 27, 17–21.
[CrossRef]
Zhou, Y.; Tao, L.; Zhou, X.; Zuo, Z.; Gong, J.; Liu, X.; Zhou, Y.; Liu, C.; Sang, N.; Liu, H.; et al. DHODH and cancer: Promising
prospects to be explored. Cancer Metab. 2021, 9, 1–25. [CrossRef]
Hey-Mogensen, M.; Goncalves, R.L.; Orr, A.L.; Brand, M.D. Production of superoxide/H2 O2 by dihydroorotate dehydrogenase
in rat skeletal muscle mitochondria. Free Radic. Biol. Med. 2014, 72, 149–155. [CrossRef]
Cells 2022, 11, 552
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
21 of 27
Popugaeva, E.; Bezprozvanny, I. Role of endoplasmic reticulum Ca2+ signaling in the pathogenesis of Alzheimer disease. Front.
Mol. Neurosci. 2013, 6, 29. [CrossRef] [PubMed]
Zorov, D.B.; Juhaszova, M.; Sollott, S.J. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiol. Rev.
2014, 94, 909–950. [CrossRef] [PubMed]
Kaludercic, N.; Mialet-Perez, J.; Paolocci, N.; Parini, A.; Di Lisa, F. Monoamine oxidases as sources of oxidants in the heart. J. Mol.
Cell. Cardiol. 2014, 73, 34–42. [CrossRef] [PubMed]
Rabilloud, T.; Heller, M.; Rigobello, M.P.; Bindoli, A.; Aebersold, R.; Lunardi, J. The mitochondrial antioxidant defence system
and its response to oxidative stress. Proteomics 2001, 1, 1105–1110. [CrossRef]
Hanukoglu, I. Antioxidant protective mechanisms against reactive oxygen species (ROS) generated by mitochondrial P450
systems in steroidogenic cells. Drug Metab. Rev. 2006, 38, 171–196. [CrossRef]
Rohan Fernando, M.; Lechner, J.M.; Löfgren, S.; Gladyshev, V.N.; Lou, M.F.; Rohan Fernando, M.; Lechner, J.M.; Löfgren, S.;
Gladyshev, V.N.; Lou, M.F. Mitochondrial thioltransferase (glutaredoxin 2) has GSH-dependent and thioredoxin reductasedependent peroxidase activities in vitro and in lens epithelial cells. FASEB J. 2006, 20, 2645–2647. [CrossRef]
Kudryavtseva, A.V.; Krasnov, G.S.; Dmitriev, A.A.; Alekseev, B.Y.; Kardymon, O.L.; Sadritdinova, A.F.; Fedorova, M.S.; Pokrovsky,
A.V.; Melnikova, N.V.; Kaprin, A.D.; et al. Mitochondrial dysfunction and oxidative stress in aging and cancer. Oncotarget 2016,
7, 44879. [CrossRef]
Kirkinezos, I.G.; Moraes, C.T. Reactive oxygen species and mitochondrial diseases. Semin. Cell Dev. Biol. 2001, 12, 449–457.
[CrossRef]
Rimessi, A.; Previati, M.; Nigro, F.; Wieckowski, M.R.; Pinton, P. Mitochondrial reactive oxygen species and inflammation: Molecular mechanisms, diseases and promising therapies. Int. J. Biochem. Cell Biol. 2016, 81, 281–293. [CrossRef]
Reshi, M.S.; Yadav, D.; Uthra, C.; Shrivastava, S.; Shukla, S. Acetaminophen-induced renal toxicity: Preventive effect of silver
nanoparticles. Toxicol. Res. 2020, 9, 406–412. [CrossRef]
Ksi˛eżakowska-Łakoma, K.; Żyła, M.; Wilczyński, J.R. Mitochondrial dysfunction in cancer. Prz. = Menopause Rev. 2014, 13, 136.
[CrossRef] [PubMed]
Zou, Z.; Chang, H.; Li, H.; Wang, S. Induction of reactive oxygen species: An emerging approach for cancer therapy. Apoptosis
2017, 22, 1321–1335. [CrossRef] [PubMed]
Stadtman, E.R.; Levine, R.L. Protein oxidation. Ann. N. Y. Acad. Sci. 2000, 899, 191–208. [CrossRef] [PubMed]
Fruhwirth, G.O.; Hermetter, A. Mediation of apoptosis by oxidized phospholipids. Lipids Health Dis. 2008, 49, 351–367.
Auten, R.L.; Whorton, M.H.; Nicholas Mason, S. Blocking neutrophil influx reduces DNA damage in hyperoxia-exposed newborn
rat lung. Am. J. Respir. Cell Mol. Biol. 2002, 26, 391–397. [CrossRef] [PubMed]
Parinandi, N.L.; Kleinberg, M.A.; Usatyuk, P.V.; Cummings, R.J.; Pennathur, A.; Cardounel, A.J.; Zweier, J.L.; Garcia, J.G.;
Natarajan, V. Hyperoxia-induced NAD (P) H oxidase activation and regulation by MAP kinases in human lung endothelial cells.
Am. J. Physiol. Lung Cell Mol. Physiol. 2003, 284, 26–38. [CrossRef]
Lei, K.; Davis, R.J. JNK phosphorylation of Bim-related members of the BCL2 family induces Bax-dependent apoptosis. Proc. Natl.
Acad. Sci. USA 2003, 100, 2432–2437. [CrossRef] [PubMed]
Di Marzo, N.; Chisci, E.; Giovannoni, R. The role of hydrogen peroxide in redox-dependent signaling: Homeostatic and
pathological responses in mammalian cells. Cells 2018, 7, 156. [CrossRef]
Linley, E.; Denyer, S.P.; McDonnell, G.; Simons, C.; Maillard, J.-Y. Use of hydrogen peroxide as a biocide: New consideration of its
mechanisms of biocidal action. J. Antimicrob. Chemother. 2012, 67, 1589–1596. [CrossRef]
Jones, D.P.; Sies, H. The Redox Code. Antioxid. Redox Signal. 2015, 23, 734–746. [CrossRef]
Sies, H. Hydrogen peroxide as a central redox signaling molecule in physiological oxidative stress: Oxidative eustress. Redox Biol.
2017, 11, 613–619. [CrossRef]
Lorenzen, I.; Mullen, L.; Bekeschus, S.; Hanschmann, E.-M. Redox regulation of inflammatory processes is enzymatically
controlled. Oxid. Med. Cell. Longev. 2017, 2017, 8459402. [CrossRef]
Veal, E.A.; Day, A.M.; Morgan, B.A. Hydrogen peroxide sensing and signaling. Mol. Cell 2007, 26, 1–14. [CrossRef]
Bienert, G.P.; Møller, A.L.B.; Kristiansen, K.A.; Schulz, A.; Møller, I.M.; Schjoerring, J.K.; Jahn, T.P. Specific aquaporins facilitate
the diffusion of hydrogen peroxide across membranes. J. Biol. Chem. 2007, 282, 1183–1192. [CrossRef] [PubMed]
Marinho, H.S.; Real, C.; Cyrne, L.; Soares, H.; Antunes, F. Hydrogen peroxide sensing, signaling and regulation of transcription
factors. Redox Biol. 2014, 2, 535–562. [CrossRef] [PubMed]
Lennicke, C.; Rahn, J.; Lichtenfels, R.; Wessjohann, L.A.; Seliger, B. Hydrogen peroxide- production, fate and role in redox
signaling of tumor cells. Cell Commun. Signal. 2015, 13, 39. [CrossRef] [PubMed]
Holmström, K.M.; Finkel, T. Cellular mechanisms and physiological consequences of redox-dependent signalling. Nat. Rev. Mol.
Cell Biol. 2014, 15, 411–421. [CrossRef]
Wang, Y.; Branicky, R.; Noë, A.; Hekimi, S. Superoxide dismutases: Dual roles in controlling ROS damage and regulating ROS
signaling. J. Cell Biol. 2018, 217, 1915–1928. [CrossRef]
Miller, A.-F. Superoxide dismutases: Ancient enzymes and new insights. FEBS Lett. 2012, 586, 585–595. [CrossRef]
Sumimoto, H.; Miyano, K.; Takeya, R. Molecular composition and regulation of the Nox family NAD(P)H oxidases. Biochem.
Biophys. Res. Commun. 2005, 338, 677–686. [CrossRef]
Cells 2022, 11, 552
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
22 of 27
Bedard, K.; Krause, K.-H. The NOX family of ROS-generating NADPH oxidases: Physiology and pathophysiology. Physiol. Rev.
2007, 87, 245–313. [CrossRef]
Panday, A.; Sahoo, M.K.; Osorio, D.; Batra, S. NADPH oxidases: An overview from structure to innate immunity-associated
pathologies. Cell. Mol. Immunol. 2015, 12, 5–23. [CrossRef]
Miller, E.W.; Dickinson, B.C.; Chang, C.J. Aquaporin-3 mediates hydrogen peroxide uptake to regulate downstream intracellular
signaling. Proc. Natl. Acad. Sci. USA 2010, 107, 15681–15686. [CrossRef]
Redza-Dutordoir, M.; Averill-Bates, D.A. Activation of apoptosis signalling pathways by reactive oxygen species. Biochim. Biophys.
Acta. Mol. Cell Res. 2016, 1863, 2977–2992. [CrossRef] [PubMed]
Willcox, J.K.; Ash, S.L.; Catignani, G.L. Antioxidants and prevention of chronic disease. Crit. Rev. Food Sci. Nutr. 2004, 44, 275–295.
[CrossRef] [PubMed]
Pacher, P.; Beckman, J.S.; Liaudet, L. Nitric oxide and peroxynitrite in health and disease. Physiol. Rev. 2007, 87, 315–424.
[CrossRef]
Genestra, M. Oxyl radicals, redox-sensitive signalling cascades and antioxidants. Cell. Signal. 2007, 19, 1807–1819. [CrossRef]
Halliwell, B. Biochemistry of oxidative stress. Biochem. Soc. Trans. 2007, 35, 1147–1150. [CrossRef] [PubMed]
Young, I.S.; Woodside, J.V. Antioxidants in health and disease. J. Clin. Pathol. 2001, 54, 176–186. [CrossRef]
Han, R.N.; Stewart, D.J. Defective lung vascular development in endothelial nitric oxide synthase-deficient mice. Trends Cardiovasc.
Med. 2006, 16, 29–34. [CrossRef]
Frei, B. Reactive oxygen species and antioxidant vitamins. Am. J. Med. 1994, 97, 5S–13S. [CrossRef]
Nishida, N.; Arizumi, T.; Takita, M.; Kitai, S.; Yada, N.; Hagiwara, S.; Inoue, T.; Minami, Y.; Ueshima, K.; Sakurai, T.; et al. Reactive
oxygen species induce epigenetic instability through the formation of 8-hydroxydeoxyguanosine in human hepatocarcinogenesis.
Dig. Dis. 2013, 31, 459–466. [CrossRef] [PubMed]
Yasui, M.; Kanemaru, Y.; Kamoshita, N.; Suzuki, T.; Arakawa, T.; Honma, M. Tracing the fates of site-specifically introduced DNA
adducts in the human genome. DNA Repair 2014, 15, 11–20. [CrossRef] [PubMed]
Pizzino, G.; Irrera, N.; Cucinotta, M.; Pallio, G.; Mannino, F.; Arcoraci, V.; Squadrito, F.; Altavilla, D.; Bitto, A. Oxidative
stress: Harms and benefits for human health. Oxid. Med. Cell. Longev. 2017, 2017, 1–13. [CrossRef] [PubMed]
O’Hagan, H.M.; Wang, W.; Sen, S.; Shields, C.D.; Lee, S.S.; Zhang, Y.W.; Clements, E.G.; Cai, Y.; Van Neste, L.; Easwaran, H.; et al.
Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG
Islands. Cancer Cell 2011, 20, 606–619. [CrossRef]
Guo, R.F.; Ward, P.A. Role of oxidants in lung injury during sepsis. Antioxid. Redox Signal. 2007, 9, 1991–2002. [CrossRef]
Hoshino, Y.; Mishima, M. Redox-based therapeutics for lung diseases. Antioxid. Redox Signal. 2008, 10, 701–704. [CrossRef]
Mahajan, A.; Tandon, V.R. Antioxidants and rheumatoid arthritis. J. Indian Rheumatol. Assoc. 2004, 12, 139–142.
Allan Butterfield, D. Amyloid β-peptide (1-42)-induced oxidative stress and neurotoxicity: Implications for neurodegeneration in
Alzheimer’s disease brain. A review. Free Radic. Res. 2002, 36, 1307–1313. [CrossRef]
Rai, S.; Hajam, Y.A.; Basheer, M.; Ghosh, H. Biochemical and histopathological inflections in hepato-renal tissues of streptozotocin
(STZ) induced diabetic male rats: Impact of exogenous melatonin administration. J. Clin. Res. Bioeth. 2016, 7, 2. [CrossRef]
Hajam, Y.A.; Rai, S.; Shree, S.; Basheer, M.; Ghosh, H. Retrieval of reproductive complications by exogenous melatonin treatment
in streptozotocin induced diabetic rat model. Res. Rev. J. Zool. Sci. 2017, 5, 96–104.
Reichmann, D.; Voth, W.; Jakob, U. Maintaining a healthy proteome during oxidative stress. Mol. Cell 2018, 69, 203–213. [CrossRef]
[PubMed]
Zhang, J.; Wang, X.; Vikash, V.; Ye, Q.; Wu, D.; Liu, Y.; Dong, W. ROS and ROS-mediated cellular signaling. Oxid. Med. Cell.
Longev. 2016, 2016, 1–18. [CrossRef]
Sies, H. Oxidative stress: A concept in redox biology and medicine. Redox Biol. 2015, 4, 180–183. [CrossRef]
Schieber, M.; Chandel, N.S. ROS function in redox signaling and oxidative stress. Curr. Biol. 2014, 24, 453–462. [CrossRef]
Yatmaz, S.; Seow, H.J.; Gualano, R.C.; Wong, Z.X.; Stambas, J.; Selemidis, S.; Crack, P.J.; Bozinovski, S.; Anderson, G.P.; Vlahos, R.
Glutathione peroxidase-1 reduces influenza A virus–induced lung inflammation. Am. J. Respir. Cell Mol. Biol. 2013, 48, 17–26.
[CrossRef]
Xu, J.; Li, T.; Wu, H.; Xu, T. Role of thioredoxin in lung disease. Pulm. Pharmacol. Ther. 2012, 25, 154–162. [CrossRef] [PubMed]
Groitl, B.; Jakob, U. Thiol-based redox switches. Biochim. Biophys. Acta Proteins Proteom. 2014, 1844, 1335–1343. [CrossRef]
Garcia-Santamarina, S.; Boronat, S.; Hidalgo, E. Reversible cysteine oxidation in hydrogen peroxide sensing and signal transduction. Biochemistry 2014, 53, 2560–2580. [CrossRef]
Go, Y.M.; Jones, D.P. Redox control systems in the nucleus: Mechanisms and functions. Antioxid. Redox Signal. 2010, 13, 489–509.
[CrossRef]
Roos, G.; Messens, J. Protein sulfenic acid formation: From cellular damage to redox regulation. Free Radic. Biol. Med. 2011, 51,
314–326. [CrossRef]
Corcoran, A.; Cotter, T.G. Redox regulation of protein kinases. FEBS J. 2013, 280, 1944–1965. [CrossRef] [PubMed]
Östman, A.; Frijhoff, J.; Sandin, Å.; Böhmer, F.D. Regulation of protein tyrosine phosphatases by reversible oxidation. J. Biochem.
2011, 150, 345–356. [CrossRef] [PubMed]
Adam-Vizi, V.; Chinopoulos, C. Bioenergetics and the formation of mitochondrial reactive oxygen species. Trends Pharmacol. Sci.
2006, 27, 639–645. [CrossRef] [PubMed]
Cells 2022, 11, 552
85.
86.
87.
88.
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
105.
106.
107.
108.
109.
110.
111.
112.
23 of 27
Song, H.; Bao, S.; Ramanadham, S.; Turk, J. Effects of biological oxidants on the catalytic activity and structure of group VIA
phospholipase A2. Biochem. 2006, 45, 6392–6406. [CrossRef]
Hajam, Y.A.; Rai, S.; Ghosh, H.; Basheer, M. Combined administration of exogenous melatonin and insulin ameliorates streptozotocin induced toxic alteration on hematological parameters in diabetic male Wistar rats. Toxicol. Rep. 2020, 7, 353–359.
[CrossRef]
Uthra, C.; Shrivastava, S.; Jaswal, A.; Sinha, N.; Reshi, M.S.; Shukla, S. Therapeutic potential of quercetin against acrylamide
induced toxicity in rats. Biomed. Pharmacother. 2017, 86, 705–714. [CrossRef]
Lobo, V.; Patil, A.; Phatak, A.; Chandra, N. Free radicals, antioxidants and functional foods: Impact on human health. Pharmacogn.
Rev. 2010, 4, 118. [CrossRef]
Birben, E.; Sahiner, U.M.; Sackesen, C.; Erzurum, S.; Kalayci, O. Oxidative stress and antioxidant defense. World Allergy Organ J.
2012, 5, 9–19. [CrossRef]
Pham-Huy, L.A.; He, H.; Pham-Huy, C. Free radicals, antioxidants in disease and health. Int. J. Biomed. 2008, 4, 89.
Valavanidis, A.; Vlachogianni, T.; Fiotakis, K.; Loridas, S. Pulmonary oxidative stress, inflammation and cancer: Respirable
particulate matter, fibrous dusts and ozone as major causes of lung carcinogenesis through reactive oxygen species mechanisms.
Int. J. Environ. Res. Public Health 2013, 10, 3886–3907. [CrossRef]
Maechler, P.; Wollheim, C.B. Mitochondrial function in normal and diabetic β-cells. Nature 2001, 414, 807–812. [CrossRef]
Hastoy, B.; Godazgar, M.; Clark, A.; Nylander, V.; Spiliotis, I.; van de Bunt, M.; Chibalina, M.V.; Barrett, A.; Burrows, C.; Tarasov,
A.I.; et al. Electrophysiological properties of human beta-cell lines EndoC-βH1 and-βH2 conform with human beta-cells. Sci. Rep.
2018, 8, 1–16. [CrossRef] [PubMed]
Rustenbeck, I.; Schulze, T.; Morsi, M.; Alshafei, M.; Panten, U. What is the metabolic amplification of insulin secretion and is it
(still) relevant? Metabolites 2021, 11, 355. [CrossRef]
Cerf, M.E. Beta cell dysfunction and insulin resistance. Front. Endocrinol. 2013, 4, 37. [CrossRef] [PubMed]
Silva, J.P.; Köhler, M.; Graff, C.; Oldfors, A.; Magnuson, M.A.; Berggren, P.O.; Larsson, N.G. Impaired insulin secretion and β-cell
loss in tissue-specific knockout mice with mitochondrial diabetes. Nat. Genet. 2000, 26, 336–340. [CrossRef] [PubMed]
Chinnery, P.F. Mitochondrial disease in adults: What’s old and what’s new? EMBO Mol. Med. 2015, 7, 1503–1512. [CrossRef]
Bhatti, J.S.; Bhatti, G.K.; Reddy, P.H. Mitochondrial dysfunction and oxidative stress in metabolic disorders—A step towards
mitochondria based therapeutic strategies. Biochim. Biophys. Acta Mol. Basis Dis. 2017, 1863, 1066–1077. [CrossRef] [PubMed]
Sergi, D.; Naumovski, N.; Heilbronn, L.K.; Abeywardena, M.; O’Callaghan, N.; Lionetti, L.; Luscombe-Marsh, N. Mitochondrial
(Dys) function and insulin resistance: From pathophysiological molecular mechanisms to the impact of diet. Front. Physiol. 2019,
10, 532. [CrossRef]
Alfadda, A.A.; Sallam, R.M. Reactive oxygen species in health and disease. J. Biomed. Biotechnol. 2012, 2012, 936486. [CrossRef]
He, L.; He, T.; Farrar, S.; Ji, L.; Liu, T.; Ma, X. Antioxidants maintain cellular redox homeostasis by elimination of reactive oxygen
species. Cell. Physiol. Biochem. 2017, 44, 532–553. [CrossRef] [PubMed]
Acharya, J.D.; Ghaskadbi, S.S. Islets and their antioxidant defense. Islets 2010, 2, 225–235. [CrossRef] [PubMed]
Chan, C.B.; De Leo, D.; Joseph, J.W.; McQuaid, T.S.; Ha, X.F.; Xu, F.; Tsushima, R.G.; Pennefather, P.S.; Salapatek, A.M.F.;
Wheeler, M.B. Increased uncoupling protein-2 levels in β-cells are associated with impaired glucose-stimulated insulin secretion:
Mechanism of action. Diabetes 2001, 50, 1302–1310. [CrossRef]
Zhu, X.F.; Zou, H.D. PEDF in diabetic retinopathy: A protective effect of oxidative stress. J. Biomed. Biotechnol. 2012, 2012, 1–8.
[CrossRef]
Chen, J.X.; Stinnett, A. Critical role of the NADPH oxidase subunit p47 phox on vascular TLR expression and neointimal lesion
formation in high-fat diet-induced obesity. Lab. Investig. 2008, 88, 1316–1328. [CrossRef]
El-Haschimi, K.; Pierroz, D.D.; Hileman, S.M.; Bjorbaek, C.; Flier, J.S. Two defects contribute to hypothalamic leptin resistance in
mice with diet-induced obesity. J. Clin. Investig. 2000, 105, 1827–1832. [CrossRef] [PubMed]
Horvath, T.L.; Andrews, Z.B.; Diano, S. Fuel utilization by hypothalamic neurons: Roles for ROS. Trends Endocrinol. Metab. 2009,
20, 78–87. [CrossRef]
Shih, N.L.; Cheng, T.H.; Loh, S.H.; Cheng, P.Y.; Wang, D.L.; Chen, Y.S.; Liu, S.H.; Liew, C.C.; Chen, J.J. Reactive oxygen
species modulate angiotensin II-induced β-myosin heavy chain gene expression via ras/raf/extracellular signal-regulated kinase
pathway in neonatal rat cardiomyocytes. Biochem. Biophys. Res. Commun. 2001, 283, 143–148. [CrossRef] [PubMed]
Li, J.M.; Gall, N.P.; Grieve, D.J.; Chen, M.; Shah, A.M. Activation of NADPH oxidase during progression of cardiac hypertrophy
to failure. Hypertension 2002, 40, 477–484. [CrossRef]
Satoh, M.; Ogita, H.; Takeshita, K.; Mukai, Y.; Kwiatkowski, D.J.; Liao, J.K. Requirement of Rac1 in the development of cardiac
hypertrophy. Proc. Natl. Acad. Sci. USA 2006, 103, 7432–7437. [CrossRef]
Higuchi, Y.; Otsu, K.; Nishida, K.; Hirotani, S.; Nakayama, H.; Yamaguchi, O.; Hikoso, S.; Kashiwase, K.; Takeda, T.; Watanabe,
T.; et al. The small GTP-binding protein Rac1 induces cardiac myocyte hypertrophy through the activation of apoptosis
signal-regulating kinase 1 and nuclear factor-κB. J. Biol. Chem. 2003, 278, 20770–20777. [CrossRef] [PubMed]
Izumiya, Y.; Kim, S.; Izumi, Y.; Yoshida, K.; Yoshiyama, M.; Matsuzawa, A.; Ichijo, H.; Iwao, H. Apoptosis signal-regulating kinase
1 plays a pivotal role in angiotensin II–induced cardiac hypertrophy and remodeling. Circ. Res. 2003, 93, 874–883. [CrossRef]
[PubMed]
Cells 2022, 11, 552
24 of 27
113. Liu, Q.; Sargent, M.A.; York, A.J.; Molkentin, J.D. ASK1 regulates cardiomyocyte death but not hypertrophy in transgenic mice.
Circ. Res. 2009, 105, 1110–1117. [CrossRef]
114. Shanmugam, P.; Valente, A.J.; Prabhu, S.D.; Venkatesan, B.; Yoshida, T.; Delafontaine, P.; Chandrasekar, B. Angiotensin-II type
1 receptor and NOX2 mediate TCF/LEF and CREB dependent WISP1 induction and cardiomyocyte hypertrophy. J. Mol. Cell.
Cardiol. 2011, 50, 928–938. [CrossRef] [PubMed]
115. Mattson, M.P. Pathways towards and away from Alzheimer’s disease. Nature 2004, 430, 631–639. [CrossRef]
116. Andreyev, A.Y.; Kushnareva, Y.E.; Starkov, A.A. Mitochondrial metabolism of reactive oxygen species. Biochem. 2005, 70, 200–214.
[CrossRef]
117. Zhao, Y.; Zhao, B. Oxidative stress and the pathogenesis of Alzheimer’s disease. Oxid. Med. Cell. Longev. 2013, 2013, 1–10.
[CrossRef]
118. Gandhi, S.; Abramov, A.Y. Mechanism of oxidative stress in neurodegeneration. Oxid. Med. Cell. Longev. 2012, 2012, 1–11.
[CrossRef]
119. Radi, E.; Formichi, P.; Battisti, C.; Federico, A. Apoptosis and oxidative stress in neurodegenerative diseases. J. Alzheimer’s Dis.
2014, 42, 125–152. [CrossRef]
120. Matsuoka, Y.; Picciano, M.; La Francois, J.; Duff, K. Fibrillar β-amyloid evokes oxidative damage in a transgenic mouse model of
Alzheimer’s disease. Neuroscience 2001, 104, 609–613. [CrossRef]
121. Murakami, K.; Murata, N.; Noda, Y.; Tahara, S.; Kaneko, T.; Kinoshita, N.; Hatsuta, H.; Murayama, S.; Barnham, K.J.; Irie, K.;
et al. SOD1 (copper/zinc superoxide dismutase) deficiency drives amyloid β protein oligomerization and memory loss in mouse
model of Alzheimer disease. J. Biol. Chem. 2011, 286, 44557–44568. [CrossRef] [PubMed]
122. Chen, L.; Na, R.; Gu, M.; Richardson, A.; Ran, Q. Lipid peroxidation up-regulates BACE1 expression in vivo: A possible early
event of amyloidogenesis in Alzheimer’s disease. J. Neurochem. 2008, 107, 197–207. [CrossRef] [PubMed]
123. Stamer, K.; Vogel, R.; Thies, E.; Mandelkow, E.; Mandelkow, E.M. Tau blocks traffic of organelles, neurofilaments, and APP
vesicles in neurons and enhances oxidative stress. J. Cell Biol. 2002, 156, 1051–1063. [CrossRef] [PubMed]
124. Yoshiyama, Y.; Higuchi, M.; Zhang, B.; Huang, S.M.; Iwata, N.; Saido, T.C.; Maeda, J.; Suhara, T.; Trojanowski, J.Q.; Lee, V.M.Y.
Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007, 53, 337–351. [CrossRef]
125. David, D.C.; Hauptmann, S.; Scherping, I.; Schuessel, K.; Keil, U.; Rizzu, P.; Ravid, R.; Dröse, S.; Brandt, U.; Müller, W.E.; et al.
Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice. J. Biol. Chem. 2005, 280,
23802–23814. [CrossRef] [PubMed]
126. Halverson, R.A.; Lewis, J.; Frausto, S.; Hutton, M.; Muma, N.A. Tau protein is cross-linked by transglutaminase in P301L tau
transgenic mice. J. Neurosci. 2005, 25, 1226–1233. [CrossRef]
127. Castellani, R.; Hirai, K.; Aliev, G.; Drew, K.L.; Nunomura, A.; Takeda, A.; Cash, A.D.; Obrenovich, M.E.; Perry, G.; Smith, M.A.
Role of mitochondrial dysfunction in Alzheimer’s disease. J. Neurosci. Res. 2002, 70, 357–360. [CrossRef]
128. Bubber, P.; Haroutunian, V.; Fisch, G.; Blass, J.P.; Gibson, G.E. Mitochondrial abnormalities in Alzheimer brain: Mechanistic
implications. Ann. Neurol. 2005, 57, 695–703. [CrossRef]
129. Wang, X.; Wang, W.; Li, L.; Perry, G.; Lee, H.G.; Zhu, X. Oxidative stress and mitochondrial dysfunction in Alzheimer’s disease.
Biochim. Biophys. Acta. Mol. Basis Dis. 2014, 1842, 1240–1247. [CrossRef]
130. Moon, H.E.; Paek, S.H. Mitochondrial dysfunction in Parkinson’s disease. Exp. Neurobiol. 2015, 24, 103–116. [CrossRef]
131. Blesa, J.; Trigo-Damas, I.; Quiroga-Varela, A.; Jackson-Lewis, V.R. Oxidative stress and Parkinson’s disease. Front. Neuroanat.
2015, 9, 91. [CrossRef] [PubMed]
132. Schapira, A.H. Mitochondria in the aetiology and pathogenesis of Parkinson’s disease. Lancet Neurol. 2008, 7, 97–109. [CrossRef]
133. Franco-Iborra, S.; Vila, M.; Perier, C. The Parkinson disease mitochondrial hypothesis: Where are we at? Neuroscientist 2016, 22,
266–277. [CrossRef]
134. Lin, M.T.; Beal, M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443, 787–795.
[CrossRef] [PubMed]
135. Hauser, D.N.; Hastings, T.G. Mitochondrial dysfunction and oxidative stress in Parkinson’s disease and monogenic parkinsonism.
Neurobiol. Dis. 2013, 51, 35–42. [CrossRef] [PubMed]
136. Buneeva, O.; Fedchenko, V.; Kopylov, A.; Medvedev, A. Mitochondrial dysfunction in Parkinson’s disease: Focus on Mitochondrial
DNA. Biomedicines 2020, 8, 591. [CrossRef]
137. Simon, D.K.; Pankratz, N.; Kissell, D.K.; Pauciulo, M.W.; Halter, C.A.; Rudolph, A.; Pfeiffer, R.F.; Nichols, W.C.; Foroud, T.
Maternal inheritance and mitochondrial DNA variants in familial Parkinson’s disease. BMC Med. Genet. 2010, 11, 1–9. [CrossRef]
138. Ellmore, T.M.; Suescun, J.; Castriotta, R.J.; Schiess, M.C. A study of the relationship between uric acid and substantia nigra brain
connectivity in patients with REM sleep behavior disorder and Parkinson’s disease. Front. Neurol. 2020, 11, 815. [CrossRef]
139. Ma, L.; Azad, M.G.; Dharmasivam, M.; Richardson, V.; Quinn, R.J.; Feng, Y.; Pountney, D.L.; Tonissen, K.F.; Mellick, G.D.; Yanatori,
I.; et al. Parkinson’s disease: Alterations in iron and redox biology as a key to unlock therapeutic strategies. Redox Biol. 2021,
41, 101896. [CrossRef]
140. Oakley, A.E.; Collingwood, J.F.; Dobson, J.; Love, G.; Perrott, H.R.; Edwardson, J.A.; Elstner, M.; Morris, C.M. Individual
dopaminergic neurons show raised iron levels in Parkinson disease. Neurology 2007, 68, 1820–1825. [CrossRef]
141. Locatelli, F.; Canaud, B.; Eckardt, K.U.; Stenvinkel, P.; Wanner, C.; Zoccali, C. Oxidative stress in end-stage renal disease: An
emerging threat to patient outcome. Nephrol. Dial. Transplant. 2003, 18, 1272–1280. [CrossRef]
Cells 2022, 11, 552
25 of 27
142. Daenen, K.; Andries, A.; Mekahli, D.; Van Schepdael, A.; Jouret, F.; Bammens, B. Oxidative stress in chronic kidney disease.
Pediatr. Nephrol. 2019, 34, 975–991. [CrossRef]
143. Annuk, M.; Zilmer, M.; Lind, L.; Linde, T.; Fellström, B. Oxidative stress and endothelial function in chronic renal failure. J. Am.
Soc. Nephrol. 2001, 12, 2747–2752. [CrossRef]
144. Dounousi, E.; Papavasiliou, E.; Makedou, A.; Ioannou, K.; Katopodis, K.P.; Tselepis, A.; Siamopoulos, K.C.; Tsakiris, D. Oxidative
stress is progressively enhanced with advancing stages of CKD. Am. J. Kidney Dis. 2006, 48, 752–760. [CrossRef]
145. Ferraro, B.; Galli, F.; Frei, B.; Kingdon, E.; Canestrari, F.; Rice-Evans, C.; Buoncristiani, U.; Davenport, A.; Moore, K.P. Peroxynitriteinduced oxidation of plasma lipids is enhanced in stable hemodialysis patients. Kidney Inter. 2003, 63, 2207–2213. [CrossRef]
[PubMed]
146. Liakopoulos, V.; Roumeliotis, S.; Gorny, X.; Dounousi, E.; Mertens, P.R. Oxidative stress in hemodialysis patients: A review of the
literature. Oxid. Med. Cell. Longev. 2017, 2014, 1–23. [CrossRef] [PubMed]
147. Krata, N.; Zagożdżon, R.; Foroncewicz, B.; Mucha, K. Oxidative stress in kidney diseases: The cause or the consequence? Arch.
Immunol. Ther. Exp. 2018, 66, 211–220. [CrossRef] [PubMed]
148. Yang, Q.; Wu, F.R.; Wang, J.N.; Gao, L.; Jiang, L.; Li, H.D.; Ma, Q.; Liu, X.Q.; Wei, B.; Zhou, L.; et al. Nox4 in renal diseases: An
update. Free Radic. Biol. Med. 2018, 124, 466–472. [CrossRef]
149. Holterman, C.E.; Thibodeau, J.F.; Kennedy, C.R. NADPH oxidase 5 and renal disease. Curr. Opin. Nephrol. Hypertens. 2015, 24,
81–87. [CrossRef]
150. Takac, I.; Schröder, K.; Zhang, L.; Lardy, B.; Anilkumar, N.; Lambeth, J.D.; Shah, A.M.; Morel, F.; Brandes, R.P. The E-loop is
involved in hydrogen peroxide formation by the NADPH oxidase Nox4. J. Biol. Chem. 2011, 286, 13304–13313. [CrossRef]
151. Monari, A.; Dumont, E. Understanding DNA under oxidative stress and sensitization: The role of molecular modeling. Front.
Chem. 2015, 3, 43.
152. Descamps-Latscha, B.; Drüeke, T.; Witko-Sarsat, V. Dialysis-induced oxidative stress: Biological aspects, clinical consequences,
and therapy. Semin. Dial. 2001, 14, 193–199. [CrossRef] [PubMed]
153. Hajam, Y.A.; Rai, S.; Pandi-Perumal, S.R.; Brown, G.M.; Reiter, R.J.; Cardinali, D.P. Coadministration of melatonin and insulin
improves diabetic-induced impairment of rat kidney function. Neuroendocrinology 2021. [CrossRef] [PubMed]
154. Zill, H.; Günther, R.; Erbersdobler, H.F.; Fölsch, U.R.; Faist, V. RAGE expression and AGE-induced MAP kinase activation in
Caco-2 cells. Biochem. Biophys. Res. Commun. 2001, 288, 1108–1111. [CrossRef] [PubMed]
155. Boulanger, E.; Wautier, M.P.; Wautier, J.L.; Boval, B.; Panis, Y.; Wernert, N.; Danze, P.M.; Dequiedt, P. AGEs bind to mesothelial
cells via RAGE and stimulate VCAM-1 expression. Kidney Inter. 2002, 61, 148–156. [CrossRef]
156. Ruiz, S.; Pergola, P.E.; Zager, R.A.; Vaziri, N.D. Targeting the transcription factor Nrf2 to ameliorate oxidative stress and
inflammation in chronic kidney disease. Kidney Inter. 2013, 83, 1029–1041. [CrossRef]
157. Reshi, M.S.; Shrivastava, S.; Jaswal, A.; Sinha, N.; Uthra, C.; Shukla, S. Gold nanoparticles ameliorate acetaminophen induced
hepato-renal injury in rats. Exp. Toxicol. Pathol. 2017, 69, 231–240. [CrossRef]
158. Modaresi, A.; Nafar, M.; Sahraei, Z. Oxidative stress in chronic kidney disease. Iran. J. Kidney. Dis. 2015, 9, 165.
159. Shokolenko, I.; Venediktova, N.; Bochkareva, A.; Wilson, G.L.; Alexeyev, M.F. Oxidative stress induces degradation of mitochondrial DNA. Nucleic Acids Res. 2009, 37, 2539–2548. [CrossRef]
160. Adesso, S.; Popolo, A.; Bianco, G.; Sorrentino, R.; Pinto, A.; Autore, G.; Marzocco, S. The uremic toxin indoxyl sulphate enhances
macrophage response to LPS. PLoS ONE 2013, 8, 76778. [CrossRef]
161. Lopez-Otln, C.; Blasco, M.A.; Partridge, L.; Serrano, M.; Kroemer, G. The hallmarks of aging. Cell 2013, 153, 1194–1217. [CrossRef]
162. Benz, C.C.; Yau, C. Ageing, oxidative stress and cancer: Paradigms in parallax. Nat. Rev. Cancer 2008, 8, 875–879. [CrossRef]
[PubMed]
163. Bonomini, F.; Rodella, L.F.; Rezzani, R. Metabolic syndrome, aging and involvement of oxidative stress. Aging Dis. 2015, 6, 109.
[CrossRef] [PubMed]
164. Liang, R.; Ghaffari, S. Stem cells, redox signaling, and stem cell aging. Antioxid. Redox Signal. 2014, 20, 1902–1916. [CrossRef]
[PubMed]
165. Martin, J.E.; Sheaff, M.T. The pathology of ageing: Concepts and mechanisms. J. Pathol. 2007, 211, 111–113. [CrossRef] [PubMed]
166. Biala, A.K.; Dhingra, R.; Kirshenbaum, L.A. Mitochondrial dynamics: Orchestrating the journey to advanced age. J. Mol. Cell.
Cardiol. 2015, 83, 37–43. [CrossRef]
167. Bratic, A.; Larsson, N.G. The role of mitochondria in aging. J. Clin. Investig. 2013, 123, 951–957. [CrossRef]
168. Indo, H.P.; Yen, H.C.; Nakanishi, I.; Matsumoto, K.I.; Tamura, M.; Nagano, Y.; Matsui, H.; Gusev, O.; Cornette, R.; Okuda, T.; et al.
A mitochondrial superoxide theory for oxidative stress diseases and aging. J. Clin. Biochem. Nutr. 2015, 56, 1–7. [CrossRef]
169. Genova, M.L.; Lenaz, G. The interplay between respiratory supercomplexes and ROS in aging. Antioxid. Redox Signal. 2015, 23,
208–238. [CrossRef]
170. Barja, G. The mitochondrial free radical theory of aging. Prog. Mol. Biol. Transl. Sci. 2014, 127, 1–27.
171. López-Lluch, G.; Santos-Ocaña, C.; Sánchez-Alcázar, J.A.; Fernández-Ayala, D.J.M.; Asencio-Salcedo, C.; Rodríguez-Aguilera, J.C.;
Navas, P. Mitochondrial responsibility in ageing process: Innocent, suspect or guilty. Biogerontology 2015, 16, 599–620. [CrossRef]
172. Bouzid, M.A.; Filaire, E.; McCall, A.; Fabre, C. Radical oxygen species, exercise and aging: An update. Sports Med. 2015, 45,
1245–1261. [CrossRef] [PubMed]
Cells 2022, 11, 552
26 of 27
173. Kwon, M.J.; Lee, K.Y.; Lee, H.W.; Kim, J.H.; Kim, T.Y. SOD3 variant, R213G, altered SOD3 function, leading to ROS-mediated
inflammation and damage in multiple organs of premature aging mice. Antioxid. Redox Signal. 2015, 23, 985–999. [CrossRef]
174. Edrey, Y.H.; Salmon, A.B. Revisiting an age-old question regarding oxidative stress. Free Radic. Biol. Med. 2014, 71, 368–378.
[CrossRef] [PubMed]
175. Bjelakovic, G.; Nikolova, D.; Gluud, C. Antioxidant supplements and mortality. Curr. Opin. Clin. Nutr. Metab. Care 2014, 17, 40–44.
[CrossRef]
176. Cunningham, G.M.; Roman, M.G.; Flores, L.C.; Hubbard, G.B.; Salmon, A.B.; Zhang, Y.; Gelfond, J.; Ikeno, Y. The paradoxical role
of thioredoxin on oxidative stress and aging. Arch. Biochem. Biophys. 2015, 576, 32–38. [CrossRef]
177. Breitenbach, M.; Rinnerthaler, M.; Hartl, J.; Stincone, A.; Vowinckel, J.; Breitenbach-Koller, H.; Ralser, M. Mitochondria in ageing:
There is metabolism beyond the ROS. FEMS Yeast Res. 2014, 14, 198–212. [CrossRef] [PubMed]
178. Lagouge, M.; Larsson, N.G. The role of mitochondrial DNA mutations and free radicals in disease and ageing. J. Intern. Med.
2013, 273, 529–543. [CrossRef] [PubMed]
179. Bertram, C.; Hass, R. Cellular responses to reactive oxygen species-induced DNA damage and aging. Biol. Chem. 2008, 389,
211–220. [CrossRef] [PubMed]
180. Fimognari, C. Role of oxidative RNA damage in chronic-degenerative diseases. Oxid. Med. Cell. Longev. 2015, 2015, 1–9.
[CrossRef] [PubMed]
181. Shimi, T.; Goldman, R.D. Nuclear lamins and oxidative stress in cell proliferation and longevity. Can. Biol. Nucl. Envel. 2014, 1,
415–430.
182. Rinnerthaler, M.; Bischof, J.; Streubel, M.K.; Trost, A.; Richter, K. Oxidative stress in aging human skin. Biomolecules 2015, 5,
545–589. [CrossRef] [PubMed]
183. Yan, L.J. Positive oxidative stress in aging and aging-related disease tolerance. Redox Biol. 2014, 2, 165–169. [CrossRef]
184. Guillaumet-Adkins, A.; Yañez, Y.; Peris-Diaz, M.D.; Calabria, I.; Palanca-Ballester, C.; Sandoval, J. Epigenetics and oxidative stress
in aging. Oxid. Med. Cell. Longev. 2017, 2017, 9175806. [CrossRef] [PubMed]
185. Area-Gomez, E.; Schon, E.A. Mitochondria-associated ER membranes and Alzheimer disease. Curr. Opin. Genet. Dev. 2016, 38,
90–96. [CrossRef]
186. Area-Gomez, E.; Schon, E.A. On the pathogenesis of Alzheimer’s Disease: The MAM hypothesis. FASEB J. 2017, 31, 864–867.
[CrossRef]
187. Watanabe, S.; Ilieva, H.; Tamada, H.; Nomura, H.; Komine, O.; Endo, F.; Jin, S.; Mancias, P.; Kiyama, H.; Yamanaka, K.
Mitochondria-associated membrane collapse is a common pathomechanism in SIGMAR1- and SOD1-linked ALS. EMBO Mol.
Med. 2016, 8, 1421–1437. [CrossRef]
188. Stoica, R.; De Vos, K.J.; Paillusion, S.; Mueller, S.; Sancho, R.M.; Lau, K.-F.; Vizcay-Barrena, G.; Lin, W.-L.; Xu, Y.-F.; Lewis, J.; et al.
ER-mitochondria associations are regulated by the VAPBPTPIP51 interaction and are disrupted by ALS/FTD-associated TDP-43.
Nat. Commun. 2014, 5, 3996. [CrossRef]
189. Stoica, R.; Paillusion, S.; Gomez-Suaga, P.; Mitchell, J.C.; Lau, D.H.; Gray, E.H.; Sancho, R.M.; Vizcay-Barrena, G.; De Vos, K.J.;
Shaw, C.E.; et al. ALS/FTD-associated FUS activates GSK-3beta to disrupt the VAPB-PTPIP51 interaction and ER-mitochondria
associations. EMBO Rep. 2016, 17, 1326–1342. [CrossRef]
190. Tubbs, E.; Rieusset, J. Metabolic signaling functions of ER-mitochondria contact sites: Role in metabolic diseases. Soc. Endocrinol.
2016, 1, 1–55. [CrossRef]
191. Tubbs, E.; Theurey, P.; Vial, G.; Bendridi, N.; Bravard, A.; Chauvin, M.-A.; Ji-Cao, J.; Zoulim, F.; Bartosch, B.; Ovize, M.; et al.
Mitochondria-associated endoplasmic reticulum membrane (MAM) integrity is required for insulin signaling and is implicated in
hepatic insulin resistance. Diabetes 2014, 63, 3279–3294. [CrossRef] [PubMed]
192. Arruda, A.P.; Pers, B.M.; Parlakgül, G.; Güney, E.; Inouye, K.; Hotamisligil, G.S. Chronic enrichment of hepatic endoplasmic
reticulummitochondria contact leads to mitochondrial dysfunction in obesity. Nat. Med. 2014, 20, 1427–1435. [CrossRef] [PubMed]
193. Sano, R.; Annunziata, I.; Patterson, A.; Moshiach, S.; Gomero, E.; Opferman, J.; Forte, M.; d’Azzo, A. GM1-ganglioside
accumulation at the mitochondria-associated ER membranes links ER stress to Ca(2+)-dependent mitochondrial apoptosis. Mol.
Cell 2009, 36, 500–511. [CrossRef] [PubMed]
194. Williamson, C.D.; Colberg-Poley, A.M. Access of viral proteins to mitochondria via mitochondria-associated membranes. Rev.
Med. Virol. 2009, 19, 147–164. [CrossRef]
195. English, A.M.; Schuler, M.H.; Xiao, T.; Kornmann, B.; Shaw, J.M.; Hughes, A.L. ERmitochondria contacts promote mitochondrialderived compartment biogenesis. J. Cell Biol. 2020, 219, 202002144. [CrossRef]
196. Goodrum, J.M.; Lever, A.R.; Coody, T.K.; Gottschling, D.E.; Hughes, A.L. Rsp5 and Mdm30 reshape the mitochondrial network in
response to age-induced vacuole stress. Mol. Biol. Cell. 2019, 30, 2141–2154. [CrossRef]
197. Schuler, M.H.; English, A.M.; Campbell, T.J.; Shaw, J.M.; Hughes, A.L. Mitochondrialderived compartments facilitate cellular
adaptation to amino acid stress. Mol. Cell 2020, 81, 3786–3802. [CrossRef]
198. Chen, Q.; Samidurai, A.; Thompson, J.; Hu, Y.; Das, A.; Willard, B.; Lesnefsky, E.J. Endoplasmic reticulum stress-mediated
mitochondrial dysfunction in aged hearts. Biochim. Biophys. Acta Mol. Basis Dis. 2020, 1866, 165899. [CrossRef]
199. Bravo, R.; Vicencio, J.M.; Parra, V.; Troncoso, R.; Munoz, J.P.; Bui, M.; Lavandero, S. Increased ER–mitochondrial coupling
promotes mitochondrial respiration and bioenergetics during early phases of ER stress. J. Cell Sci. 2011, 124, 2143–2152. [CrossRef]
Cells 2022, 11, 552
27 of 27
200. Glancy, B.; Balaban, R.S. Role of mitochondrial Ca2+ in the regulation of cellular energetics. Biochemistry 2012, 51, 2959–2973.
[CrossRef]
201. Honrath, B.; Metz, I.; Bendridi, N.; Rieusset, J.; Culmsee, C.; Dolga, A.M. Glucoseregulated protein 75 determines ERmitochondrial coupling and sensitivity to oxidative stress in neuronal cells. Cell Death Discov. 2017, 3, 17076. [CrossRef]
[PubMed]
202. Liu, X.; Hajnoczky, G. Ca2+ -dependent regulation of mitochondrial dynamics by the Miro-Milton complex. Int. J. Biochem. Cell
Biol. 2009, 41, 1972–1976. [CrossRef] [PubMed]
203. Knupp, J.; Arvan, P.; Chang, A. Increased mitochondrial respiration promotes survival from endoplasmic reticulum stress. Cell
Death Differ. 2019, 26, 487–501. [CrossRef]
204. Yang, S.; Zhou, R.; Zhang, C.; He, S.; Su, Z. Mitochondria-associated endoplasmic reticulum membranes in the pathogenesis of
type 2 diabetes mellitus. Front. Cell Dev. Biol. 2020, 8, 935. [CrossRef] [PubMed]
205. Conklin, K.A. Chemotherapy-associated oxidative stress: Impact on chemotherapeutic effectiveness. Integr. Cancer Ther. 2004, 3,
294–300. [CrossRef]
206. Marullo, R.; Werner, E.; Degtyareva, N.; Moore, B.; Altavilla, G.; Ramalingam, S.S.; Doetsch, P.W. Cisplatin induces a mitochondrialROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions. PLoS ONE
2013, 8, 81162. [CrossRef] [PubMed]
207. Salehi, F.; Behboudi, H.; Kavoosi, G.; Ardestani, S.K. Oxidative DNA damage induced by ROS-modulating agents with the ability
to target DNA: A comparison of the biological characteristics of citrus pectin and apple pectin. Sci. Rep. 2018, 8, 1–16. [CrossRef]
[PubMed]
208. Cannan, W.J.; Tsang, B.P.; Wallace, S.S.; Pederson, D.S. Nucleosomes suppress the formation of double-strand DNA breaks during
attempted base excision repair of clustered oxidative damages. J. Biochem. 2014, 289, 19881–19893. [CrossRef]
209. Curtin, N.J. DNA repair dysregulation from cancer driver to therapeutic target. Nat. Rev. Cancer. 2012, 12, 801–817. [CrossRef]
210. Sancar, A.; Lindsey-Boltz, L.A.; Unsal-Kacmaz, K.; Linn, S. Molecular mechanisms of mammalian DNA repair and the DNA
damage checkpoints. Annu. Rev. Biochem. 2004, 73, 39–85. [CrossRef]
211. Goldstein, M.; Kastan, M.B. The DNA damage response: Implications for tumor responses to radiation and chemotherapy. Annu.
Rev. Med. 2015, 66, 129–143. [CrossRef]
212. Ciccia, A.; Elledge, S.J. The DNA damage response: Making it safe to play with knives. Mol. Cell. 2010, 40, 179–204. [CrossRef]
[PubMed]
213. McNally, J.P.; Millen, S.H.; Chaturvedi, V.; Lakes, N.; Terrell, C.E.; Elfers, E.E.; Carroll, K.R.; Hogan, S.P.; Andreassen, P.R.; Kanter,
J. Manipulating DNA damage-response signaling for the treatment of immune-mediated diseases. Proc. Natl. Acad. Sci. USA
2017, 114, 4782–4791. [CrossRef]
214. Polo, S.E.; Jackson, S.P. Dynamics of DNA damage response proteins at DNA breaks: A focus on protein modifications. Genes Dev.
2011, 25, 409–433. [CrossRef]
215. Elmore, S. Apoptosis: A review of programmed cell death. Toxicol. Pathol. 2007, 35, 495–516. [CrossRef]
216. Maréchal, A.; Zou, L. DNA damage sensing by the ATM and ATR kinases. Cold Spring Harb Perspect Biol. 2013, 5, 012716.
[CrossRef]
217. Altieri, F.; Grillo, C.; Maceroni, M.; Chichiarelli, S. DNA damage and repair: From molecular mechanisms to health implications.
Antioxid Redox Signal. 2008, 10, 891–938. [CrossRef] [PubMed]
218. Robertson, A.B.; Klungland, A.; Rognes, T.; Leiros, I. DNA repair in mammalian cells: Base excision repair, the long and short of
it. Cell Mol Life Sci. 2009, 66, 981–993. [CrossRef] [PubMed]
Oxidative Stress in Human Pathology and Aging: Molecular Mechanisms and Perspectives
Cells, 2022
Reactive oxygen and nitrogen species (RONS) are generated through various endogenous and exogenous processes; however, they are neutralized by enzymatic and non-enzymatic antioxidants. An imbalance between the generation and neutralization of oxidants results in the progression to oxidative stress (OS), which in turn gives rise to various diseases, disorders and aging. The characteristics of aging include the progressive loss of function in tissues and organs. The theory of aging explains that age-related functional losses are due to accumulation of reactive oxygen species (ROS), their subsequent damages and tissue deformities. Moreover, the diseases and disorders caused by OS include cardiovascular diseases [CVDs], chronic obstructive pulmonary disease, chronic kidney disease, neurodegenerative diseases and cancer. OS, induced by ROS, is neutralized by different enzymatic and non-enzymatic antioxidants and prevents cells, tissues and organs from damage. However, prolonged OS decrea......Read more
